Modified recombinant adeno-associated virus (AAV)-binding protein and method for purifying aav
The enhanced alkaline-resistant recombinant AAV-binding protein facilitates efficient purification of full AAV vectors through specific substitutions and chromatographic methods, addressing the inefficiencies in existing purification techniques and improving therapeutic efficacy.
Patent Information
- Application Number
- PCT/JP2024/018896
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-10
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for purifying adeno-associated virus (AAV) vectors, particularly for distinguishing between full and empty vectors, are inefficient and prone to contamination due to limited alkaline resistance of existing AAV-binding proteins, which affects the efficacy and safety of therapeutic applications.
Development of a recombinant AAV-binding protein with enhanced alkaline resistance through specific amino acid substitutions, allowing for improved purification using affinity chromatography followed by anion exchange chromatography to achieve high-purity full AAV vectors.
The modified AAV-binding protein enables efficient and pure purification of full AAV vectors, reducing the risk of side effects and enhancing the therapeutic efficacy by effectively separating full and empty vectors.
Smart Images

Figure JP2024018896_28112024_PF_FP_ABST
Abstract
Description
Modified recombinant adeno-associated virus (AAV) binding proteins and methods for purifying AAV
[0001] The present disclosure relates to proteins that have binding activity to adeno-associated viruses (AAV). In one aspect, the present disclosure relates to improved recombinant AAV binding proteins, for example, with improved alkaline resistance.
[0002] In one aspect, the present disclosure relates to a method for purifying adeno-associated virus (AAV). In another aspect, the present disclosure relates to a method that allows for easy purification of an AAV vector containing a gene, for example.
[0003] Adeno-associated virus (AAV) is a non-enveloped virus classified in the Parvoviridae family, Dependovirus genus. The AAV envelope particle is composed of three types of proteins (VP1, VP2, and VP3), and approximately 60 protein molecules are mixed and assembled in a ratio of VP1:VP2:VP3 = 1:1:10, resulting in a regular icosahedral shape with a diameter of 20 to 30 nm.
[0004] In nature, AAV lacks the ability to replicate autonomously and depends on helper viruses such as adenoviruses and herpesviruses for replication. In the presence of the helper virus, the AAV genome replicates in the host cell, forming complete AAV particles containing the AAV genome, which are then released from the host cell. On the other hand, in the absence of the helper virus, the AAV genome is maintained in an episome or integrated into the host chromosome (latent state).
[0005] AAV is capable of infecting cells of a wide range of species, including humans, and can also infect non-dividing cells that have completed differentiation, such as blood cells, muscle, and nerve cells. It is not pathogenic to humans, so there is little concern about side effects. In addition, the virus particles are physicochemically stable. For these reasons, AAV is attracting attention as a potential vector for gene transfer aimed at treating congenital genetic diseases.
[0006] A recombinant AAV vector (hereinafter also referred to simply as an AAV vector) is typically produced by introducing a nucleic acid encoding elements essential for AAV particle formation into cells to produce cells capable of producing AAV (hereinafter also referred to as an AAV-producing cell), and then culturing the cells to express the elements essential for AAV particle formation. The produced AAV vector is recovered and purified from the AAV-producing cell to obtain a therapeutic AAV vector preparation.
[0007] A method for recovering and purifying an AAV vector from AAV-producing cells involves affinity chromatography based on the binding affinity with AAV, using an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the carrier, which allows recovery and purification of the vector from a solution containing the AAV vector in the presence of contaminants. As a specific example, Patent Document 1 discloses a polypeptide comprising the extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L (UniProt No. Q8IZA0), but with amino acid residues at specific positions in these domains substituted with other amino acid residues, thereby improving stability against heat, acid, and alkali. This polypeptide is used as an AAV-binding protein (hereinafter also referred to simply as "ligand protein") to be immobilized on an insoluble carrier, thereby achieving high-purity purification of an AAV vector.
[0008] On the other hand, when the above-mentioned adsorbent is used for purification purposes, after AAV purification, the remaining AAV and impurities are usually washed with an alkaline solution of sodium hydroxide at a high concentration (e.g., 0.1 M to 0.5 M). Therefore, there has been a demand for the creation of a ligand protein that can withstand such alkaline washing.
[0009] The produced AAV vectors include those containing genes (full AAV vectors) and those not containing genes (empty AAV vectors). Of these, empty AAV vectors may reduce the efficacy of therapeutic drugs or induce side effects due to overdosing (Non-Patent Document 2). Therefore, for use as a therapeutic AAV vector formulation, it is necessary to purify the full AAV vectors from the produced AAV vectors to a high purity.
[0010] A known method for purifying AAV vectors is affinity chromatography using an AAV adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the carrier (Patent Documents 1 and 2, and Non-Patent Document 2). However, even when purification is performed by affinity chromatography, it is difficult to remove empty AAV vectors.
[0011] A known method for obtaining a full AAV vector involves ultracentrifuging a solution containing the produced AAV vector to obtain a fraction rich in the full AAV vector. However, ultracentrifugation requires complicated steps such as preparing a solution for density gradient, ultracentrifugation, and obtaining fractions, and it generally takes several days to obtain a full AAV vector. Furthermore, since it is difficult to distinguish a fraction rich in the full AAV vector, there is a risk of collecting layers before and after the fraction collection, and there is a high risk of contamination with impurities.
[0012] Also, a method for separating full and empty AAV vectors using Tosoh TSKgel Q-STAT as an anion exchange gel and choline chloride as an eluent has been reported (Non-Patent Document 3).
[0013] WO2021 / 106882 Special Publication No. 2018-507707
[0014] Gerard A et al. , Pharm Res, 36, 29 (2019) Kai G et al. , Mol Ther Methods Clin Dev, 1:9 (2014) Sam Kurth et al. , Anal Biochem, 686, 115421 (2024)
[0015] As described above, the adeno-associated virus (AAV) binding protein disclosed in WO2021 / 106882 has improved stability against heat, acid, and alkali compared to the native form (AAV binding protein without amino acid substitution). Meanwhile, a ligand protein that is more resistant to alkaline washing than the AAV binding protein disclosed in the publication was desired.
[0016] Therefore, in one aspect, an object of the present disclosure is to provide an AAV binding protein that has improved alkali resistance compared to the AAV binding protein disclosed in the above publication.
[0017] As mentioned above, AAV vectors that do not contain genes (empty AAV vectors) may have reduced efficacy as therapeutic agents or may induce side effects due to overdosing. Therefore, for use as therapeutic AAV vector preparations, it has been necessary to highly purify AAV vectors that contain genes (full AAV vectors) from the produced AAV vectors.
[0018] Therefore, in one aspect, an object of the present disclosure is to provide a method by which a full AAV vector can be purified with high purity and easily. In one example of such an aspect, an object of the present disclosure is to provide a method by which a full AAV vector can be purified with high purity and easily from a solution containing an AAV vector obtained, for example, by culturing AAV-producing cells.
[0019] As a result of extensive research to solve the above problems, the present inventors have found that alkaline resistance can be significantly improved by substituting specific amino acid residues among the amino acid residues that constitute the adeno-associated virus (AAV) binding protein with other amino acid residues.
[0020] Furthermore, the present inventors have found that full AAV vectors can be highly purified by purifying a solution containing an AAV vector by affinity chromatography using an AAV-binding protein as a ligand, and then further subjecting the solution to anion exchange chromatography.
[0021] That is, the present invention includes the following aspects [1] to
[15] . [1] An AAV-binding protein selected from any of the following (i) to (iii): (i) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, with the proviso that at least one of the following amino acid substitutions (1) to (74) has occurred in the amino acid residues at positions 25 to 213, and which has AAV-binding activity; (1) a substitution of threonine at position 139 in SEQ ID NO: 2 with alanine; (2) a substitution of isoleucine at position 32 in SEQ ID NO: 2 with asparagine; (3) a substitution of leucine at position 34 in SEQ ID NO: 2 with glutamine; (4) a substitution of leucine at position 41 in SEQ ID NO: 2 with proline; (5) a substitution of asparagine at position 42 in SEQ ID NO: 2 with lysine or serine; (6) a substitution of valine at position 45 in SEQ ID NO: 2 with alanine; (7) a substitution of valine at position 48 in SEQ ID NO: 2 with alanine; (8) a substitution of lysine at position 51 in SEQ ID NO: 2 with arginine. (9) Glutamic acid at position 53 of SEQ ID NO:2 is replaced with glycine. (10) Threonine at position 56 of SEQ ID NO:2 is replaced with alanine or serine. (11) Tyrosine at position 57 of SEQ ID NO:2 is replaced with phenylalanine. (12) Aspartic acid at position 58 of SEQ ID NO:2 is replaced with glycine. (13) Glutamine at position 60 of SEQ ID NO:2 is replaced with lysine. (14) Threonine at position 63 of SEQ ID NO:2 is replaced with alanine. (15) Glutamic acid at position 73 of SEQ ID NO:2 is replaced with aspartic acid. (16) Glutamine at position 78 of SEQ ID NO:2 is replaced with arginine. (17) Isoleucine at position 79 of SEQ ID NO:2 is replaced with phenylalanine. (18) Leucine at position 80 of SEQ ID NO:2 is replaced with proline. (19) Lysine at position 81 of SEQ ID NO:2 is replaced with arginine. (20) Leucine at position 82 of SEQ ID NO:2 is replaced with serine. (21) Asparagine at position 84 of SEQ ID NO: 2 is substituted with aspartic acid or serine. (22) Leucine at position 89 of SEQ ID NO: 2 is substituted with proline. (23) Tyrosine at position 90 of SEQ ID NO: 2 is substituted with phenylalanine or asparagine. (24) Glutamic acid at position 91 of SEQ ID NO: 2 is substituted with glycine. (25) Tyrosine at position 92 of SEQ ID NO: 2 is substituted with serine.(26) Alanine at position 94 of SEQ ID NO:2 is replaced with threonine. (27) Valine at position 95 of SEQ ID NO:2 is replaced with isoleucine. (28) Glutamic acid at position 97 of SEQ ID NO:2 is replaced with aspartic acid. (29) Histidine at position 102 of SEQ ID NO:2 is replaced with arginine. (30) Valine at position 107 of SEQ ID NO:2 is replaced with alanine or isoleucine. (31) Valine at position 109 of SEQ ID NO:2 is replaced with glutamic acid. (32) Threonine at position 110 of SEQ ID NO:2 is replaced with alanine or serine. (33) Glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine. (34) Proline at position 115 of SEQ ID NO:2 is replaced with serine. (35) Valine at position 125 of SEQ ID NO:2 is replaced with alanine. (36) Aspartic acid at position 148 of SEQ ID NO:2 is replaced with alanine. (37) Glutamic acid at position 166 of SEQ ID NO:2 is replaced with aspartic acid. (38) Glutamic acid at position 167 of SEQ ID NO:2 is replaced with aspartic acid. (39) Alanine at position 174 of SEQ ID NO:2 is replaced with proline. (40) Serine at position 179 of SEQ ID NO:2 is replaced with threonine. (41) Glutamine at position 180 of SEQ ID NO:2 is replaced with asparagine. (42) Asparagine at position 185 of SEQ ID NO:2 is replaced with lysine. (43) Lysine at position 210 of SEQ ID NO:2 is replaced with glutamic acid. (44) Aspartic acid at position 213 of SEQ ID NO:2 is replaced with asparagine. (45) Glycine at position 27 of SEQ ID NO:2 is replaced with aspartic acid. (46) Aspartic acid at position 30 of SEQ ID NO:2 is replaced with glycine. (47) Glutamine at position 31 of SEQ ID NO:2 is replaced with arginine. (48) Proline at position 35 of SEQ ID NO:2 is replaced with alanine. (49) Substitution of glutamic acid at position 38 of SEQ ID NO:2 with valine (50) Substitution of glutamine at position 60 of SEQ ID NO:2 with arginine (51) Substitution of glutamic acid at position 75 of SEQ ID NO:2 with aspartic acid (52) Substitution of histidine at position 76 of SEQ ID NO:2 with proline (53) Substitution of tyrosine at position 92 of SEQ ID NO:2 with asparagine (54) Substitution of glycine at position 105 of SEQ ID NO:2 with glutamic acid (55) Substitution of valine at position 111 of SEQ ID NO:2 with alanine (56) Substitution of glutamic acid at position 112 of SEQ ID NO:2 with lysine (57) Substitution of arginine at position 119 of SEQ ID NO:2 with histidine(58) Glutamine at position 128 of SEQ ID NO:2 is replaced with arginine. (59) Phenylalanine at position 129 of SEQ ID NO:2 is replaced with leucine. (60) Leucine at position 134 of SEQ ID NO:2 is replaced with proline. (61) Serine at position 146 of SEQ ID NO:2 is replaced with glycine. (62) Threonine at position 147 of SEQ ID NO:2 is replaced with serine. (63) Aspartic acid at position 150 of SEQ ID NO:2 is replaced with valine. (64) Glutamic acid at position 158 of SEQ ID NO:2 is replaced with lysine. (65) Lysine at position 168 of SEQ ID NO:2 is replaced with arginine. (66) Serine at position 170 of SEQ ID NO:2 is replaced with arginine. (67) Threonine at position 187 of SEQ ID NO:2 is replaced with arginine. (68) Threonine at position 191 of SEQ ID NO:2 is replaced with isoleucine. (69) Alanine at position 198 of SEQ ID NO:2 is replaced with valine. (70) A substitution of threonine at position 199 of SEQ ID NO: 2 with alanine; (71) A substitution of leucine at position 206 of SEQ ID NO: 2 with methionine; (72) A substitution of asparagine at position 209 of SEQ ID NO: 2 with glutamic acid; (73) A substitution of valine at position 212 of SEQ ID NO: 2 with isoleucine; (74) A substitution of aspartic acid at position 213 of SEQ ID NO: 2 with glycine; (ii) An AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 of the amino acid sequence set forth in SEQ ID NO: 2, provided that at least one of the amino acid substitutions selected from (1) to (74) has occurred in the amino acid residues at positions 25 to 213, and further comprising any one or more substitutions, deletions, insertions, and additions of one or several amino acid residues at one or several positions other than the amino acid substitutions shown in (1) to (74), and having AAV-binding activity; (iii) An AAV binding protein comprising an amino acid sequence having 70% or more identity to the entire amino acid sequence of SEQ ID NO: 2 in which at least one amino acid substitution selected from (1) to (74) has occurred in the amino acid sequence from serine at position 25 to aspartic acid at position 213, and in which at least one amino acid substitution remains, and which has AAV binding activity. [2] The AAV binding protein of [1], selected from any of the following (iv) to (vi):(iv) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, with the proviso that at least the amino acid substitution (1) below has occurred in the amino acid residues at positions 25 to 213, and which has AAV-binding activity; (1) threonine at position 139 in SEQ ID NO: 2 is replaced with alanine; (v) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, with the proviso that at least the amino acid substitution (1) has occurred in the amino acid residues at positions 25 to 213, and which further comprises any one or more of substitution, deletion, insertion, and addition of one or several amino acid residues at one or several positions in addition to the amino acid substitutions set forth in (1), and which has AAV-binding activity; (vi) An AAV-binding protein comprising an amino acid sequence from the serine at position 25 to the aspartic acid at position 213 of the amino acid sequence set forth in SEQ ID NO: 2, which has 70% or more identity to the entire amino acid sequence in which at least one of the amino acid substitutions in (1) has occurred, and in which at least one of the amino acid substitutions remains, and which has AAV-binding activity. [3] The AAV-binding protein of [1] or [2], which comprises at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence of SEQ ID NO: 2, with the proviso that at least one of the amino acid substitutions shown in any of the following (A) to (P) has occurred in the amino acid residues from positions 25 to 213, and which has AAV-binding activity: (A) asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, and threonine at position 139 of SEQ ID NO: 2 is substituted with alanine; or (B) lysine at position 51 of SEQ ID NO: 2 is substituted with arginine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, and alanine at position 174 of SEQ ID NO: 2 is substituted with proline.(C) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, and alanine at position 174 of SEQ ID NO:2 is substituted with proline. (D) Lysine at position 51 of SEQ ID NO:2 is substituted with arginine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, and alanine at position 174 of SEQ ID NO:2 is substituted with proline. (E) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, lysine at position 51 of SEQ ID NO:2 is substituted with arginine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, and alanine at position 174 of SEQ ID NO:2 is substituted with proline. (F) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, and glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine. (G) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and threonine at position 187 of SEQ ID NO:2 is substituted with arginine. (H) Asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, valine at position 107 of SEQ ID NO: 2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, alanine at position 174 of SEQ ID NO: 2 is substituted with proline, glutamine at position 180 of SEQ ID NO: 2 is substituted with asparagine, and threonine at position 187 of SEQ ID NO: 2 is substituted with arginine.(I) Asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, lysine at position 168 of SEQ ID NO: 2 is substituted with arginine, alanine at position 174 of SEQ ID NO: 2 is substituted with proline, glutamine at position 180 of SEQ ID NO: 2 is substituted with asparagine, and threonine at position 187 of SEQ ID NO: 2 is substituted with arginine. (J) Asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO: 2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO: 2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, lysine at position 168 of SEQ ID NO: 2 is substituted with arginine, alanine at position 174 of SEQ ID NO: 2 is substituted with proline, and glutamine at position 180 of SEQ ID NO: 2 is substituted with asparagine. (K) Asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO: 2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO: 2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, lysine at position 168 of SEQ ID NO: 2 is substituted with arginine, alanine at position 174 of SEQ ID NO: 2 is substituted with proline, glutamine at position 180 of SEQ ID NO: 2 is substituted with asparagine, and threonine at position 187 of SEQ ID NO: 2 is substituted with arginine. (L) Glycine at position 27 of SEQ ID NO:2 is substituted with aspartic acid, asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, and glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine.(M) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid. (N) Asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO: 2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO: 2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, lysine at position 168 of SEQ ID NO: 2 is substituted with arginine, alanine at position 174 of SEQ ID NO: 2 is substituted with proline, glutamine at position 180 of SEQ ID NO: 2 is substituted with asparagine, and valine at position 212 of SEQ ID NO: 2 is substituted with isoleucine. (O) A polynucleotide encoding the AAV binding protein according to any one of [1] to [3], wherein glycine at position 27 of SEQ ID NO: 2 is substituted with aspartic acid, asparagine at position 42 of SEQ ID NO: 2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO: 2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO: 2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO: 2 is substituted with glycine, threonine at position 139 of SEQ ID NO: 2 is substituted with alanine, lysine at position 168 of SEQ ID NO: 2 is substituted with arginine, alanine at position 174 of SEQ ID NO: 2 is substituted with proline, glutamine at position 180 of SEQ ID NO: 2 is substituted with asparagine, lysine at position 210 of SEQ ID NO: 2 is substituted with glutamic acid, and valine at position 212 of SEQ ID NO: 2 is substituted with isoleucine. [4] A polynucleotide encoding the AAV binding protein according to any one of [1] to [3], [5] An expression vector comprising the polynucleotide according to [4], [6] A transformant obtained by transforming Escherichia coli with the expression vector according to [5]. [7]
[0023] A method for producing an AAV-binding protein, comprising the steps of expressing the AAV-binding protein by culturing the transformant according to [6], and recovering the expressed AAV-binding protein from the resulting culture. [8] An AAV adsorbent comprising an insoluble carrier and the AAV-binding protein according to any one of [1] to [3] immobilized on the carrier. [9] A column comprising the AAV adsorbent according to [8].
[10] A method for purifying or analyzing AAV, comprising the steps of adding a solution containing AAV to the column according to [9] to adsorb the AAV to the adsorbent, and eluting the AAV adsorbed to the adsorbent with an elution solution.
[11] The method for purifying or analyzing AAV according to
[10] , further comprising the step of washing the AAV adsorbent with an alkaline solution after the step of eluting AAV.
[12] A method for purifying AAV contained in a sample, comprising the steps of: adding a sample containing AAV to an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the insoluble carrier, thereby adsorbing the AAV to the adsorbent; eluting the AAV adsorbed to the adsorbent; adding a fraction containing AAV eluted in the elution step to an anion exchange chromatography carrier, thereby adsorbing the AAV to the anion exchange chromatography carrier; and eluting the AAV adsorbed to the anion exchange chromatography carrier.
[13] A method for purifying AAV contained in a sample, comprising the steps of adding the sample containing AAV to an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the insoluble carrier, thereby adsorbing the AAV to the adsorbent, eluting the AAV adsorbed to the adsorbent, adding the AAV-containing fraction eluted in the elution step to an anion exchange chromatography carrier, thereby adsorbing the AAV to the anion exchange chromatography carrier, and eluting the AAV adsorbed to the anion exchange chromatography carrier, wherein the AAV-binding protein is the AAV-binding protein according to any one of [1] to [3].
[14]
[14] The method of
[13] , wherein the step of eluting the AAV adsorbed on the anion exchange chromatography carrier is a step of eluting the AAV adsorbed on the carrier with an eluent having a conductivity of 13.5 mS / cm or less, and then eluting the AAV remaining on the carrier with an eluent having a conductivity of 15.0 mS / cm or more.
[0022] This is a chromatogram obtained by applying a solution containing an AAV vector (AAV8-EGFP) to affinity chromatography (AVR29c column). This is a chromatogram obtained by applying a fraction containing AAV8-EGFP purified using an AVR29c column to anion exchange chromatography (GigaCapQ column). This is a chromatogram obtained by directly applying a solution containing AAV8-EGFP to a GigaCapQ column. Each peak shown in the chromatogram in Figure 3 was analyzed by size exclusion chromatography (G6000PW XL1 is a chromatogram obtained by applying a fraction containing AAV8-EGFP purified on an AVR29c column to an anion exchange chromatography column (SkillPak GigaCapQ column, capacity 1.0 mL). The purity of AVR29c and AVR29c(-) was confirmed by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). 2 is a diagram showing the results of evaluating the binding affinity of AVR29c or AVR29c(-) to VLP2. 3 is a diagram showing the results of evaluating the elution property of AAV8 adsorbed on an AVR29c column or an AVR29c(-) column. 4 is a chromatogram obtained by applying a fraction containing AAV8-EGFP purified on an AVR29c column to an anion exchange chromatography column (SkillPak GigaCapQ column, capacity 1.0 mL). The chromatograms are obtained by adjusting the mixing ratio for eluting impurities between solution AEX-A and solution AEX-C, which is a 20 mmol / L Tris-HCl buffer (pH 9.0) containing 300 mmol / L choline chloride, to (a) 49.0%, (b) 48.0%, (c) 47.0%, and (d) 46.5%. The chromatograms are obtained by applying a fraction containing AAV8-EGFP purified on an AVR29c column to a SkillPak GigaCap Q column (volume 5.0 mL). (a) is a chromatogram obtained by affinity chromatography (AF) purification using an AVR29c column. 9(b) is a chromatogram obtained by anion exchange chromatography (AEX) purification using a SkillPak GigaCapQ column. This figure compares the positive rates when cells were infected with the AAV8-EGFP solution obtained in Example 24(1) (peak indicated by the black arrow in FIG. 9(a)), the elution fractions obtained in Examples 24(3) (peak indicated by the white arrow in FIG. 9(b)), and (4) (peak indicated by the black arrow in FIG. 9(b)). The infection dose shown on the X-axis is expressed as the number of particles per cell in (a). The infection dose shown on the X-axis is expressed as the number of vector genomes (VG) per cell in (b).
[0023] The present disclosure will be described in detail below.
[0024] As used herein, the AAV-binding protein refers to a protein that contains at least the amino acid residues from serine (S) at position 312 to aspartic acid (D) at position 500, which are regions corresponding to extracellular region domain 1 (PKD1) and domain 2 (PKD2) in the amino acid sequence of KIAA0319L (UniProt No. Q8IZA0) set forth in SEQ ID NO: 1, which is a native AAV-binding protein, provided that amino acid substitutions have occurred at specific positions in the amino acid residues at positions 312 to 500. Thus, the AAV-binding protein of the present disclosure may also contain all or part of the other extracellular region domains (domain 3 (PKD3), domain 4 (PKD4), and domain 5 (PKD5)) located on the C-terminal side of the protein. Furthermore, the AAV-binding protein of the present disclosure may comprise all or part of a signal sequence or a cysteine-rich region, such as a MANSC (Motif At N terminus with Seven Cysteines) domain, located on the N-terminal side of PKD1. Furthermore, the AAV-binding protein of the present disclosure may comprise all or part of a transmembrane region and an intracellular region located on the N-terminal and / or C-terminal side of the extracellular region.
[0025] Specifically, the amino acid substitutions at the specific positions include at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid residues from position 312 to position 500 include at least the following amino acid substitutions: V317D (this notation indicates that valine at position 317 in SEQ ID NO: 1 is substituted with aspartic acid, the same applies hereinafter), N324H, V326A, A330V, Q334L, E335V, T341A, Y342S, K362E, K371N, F379Y, K380R, V381A, I382V, G390S, K399E, K467Q, S476R, S482T, N487D, and N492D, and I319N, L321Q , L328P, N329K, N329S, V332A, E(V)335A (this notation indicates that glutamic acid at position 335 of SEQ ID NO: 1 is first substituted with valine in SEQ ID NO: 2 and then further substituted with alanine, the same applies below), K338R, E340G, T343A, T343S, Y344F, D345G, Q347K, T350A, E360D, Q365R, I366F, L367P, K368R, L369S, K(N)371D, K(N)371S, L376P, Y377F, Y377N, E378G, F(Y)379S, V(A)381T, I(V)382I, E384D, H389R, V394A, V394I, V396E, T397A, T397S, E401G, P402 S, V412A, T426A, D435A, E453D, E454D, A461P, S466T, K(Q)467N, N472K, K497E, D500N, G314D, V(D)317G, Q318R, P322A, E325V, At least one of the amino acid substitutions Q347R, E362D, H363P, F(Y)379N, G392E, V398A, K(E)399K, R406H, Q415R, F416L, L421P, S433G, T434S, D437V, E445K, K455R, S457R, T474R, T478I, A485V, T486A, L493M, N496D, V499I, and D500G is preferred because it improves alkaline stability. Among these, an AAV binding protein having at least the amino acid substitution T426A is a more preferred embodiment.
[0026] An AAV binding protein consisting of amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO: 1, with the proviso that amino acid substitutions V317D, N324H, V326A, A330V, Q334L, E335V, T341A, Y342S, K362E, K371N, F379Y, K380R, V381A, I382V, G390S, K399E, K467Q, S476R, S482T, N487D, and N492D have occurred in the amino acid residues at positions 312 to 500, is synonymous with an AAV binding protein consisting of amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2. The positions of amino acid residues in SEQ ID NO: 2 correspond to the positions of the amino acid residues in SEQ ID NO: 1 minus 287. Specifically, the V317D amino acid substitution corresponds to the substitution of the amino acid residue at position 30 in SEQ ID NO:2, and the T426A amino acid substitution corresponds to the substitution of the amino acid residue at position 139 in SEQ ID NO:2.
[0027] In the AAV-binding protein of the present disclosure, there is no particular limitation on the number of amino acids to be substituted. Examples include the AAV-binding proteins shown in any of (A) to (P) below. These AAV-binding proteins are more preferred in terms of their improved alkali stability.
[0028] (A) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the amino acid substitutions N329K, E401G, and T426A have occurred in the amino acid residues at positions 25 to 213.
[0029] (B) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the amino acid substitutions K338R, T426A, and A461P have occurred in the amino acid residues at positions 25 to 213.
[0030] (C) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, E401G, T426A, and A461P.
[0031] (D) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: K338R, E401G, T426A, and A461P.
[0032] (E) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, K338R, E401G, T426A, and A461P.
[0033] (F) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, E401G, T426A, A461P, and K(Q)467N.
[0034] (G) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, I366F, E401G, T426A, A461P, K(Q)467N, and T474R.
[0035] (H) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, V394A, E401G, T426A, A461P, K(Q)467N, and T474R.
[0036] (I) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, E401G, T426A, K455R, A461P, K(Q)467N, and T474R.
[0037] (J) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, I366F, V394A, E401G, T426A, K455R, A461P, and K(Q)467N.
[0038] (K) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, I366F, V394A, E401G, T426A, K455R, A461P, K(Q)467N, and T474R.
[0039] (L) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: G314D, N329K, I366F, V394A, E401G, T426A, K455R, A461P, and K(Q)467N.
[0040] (M) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, I366F, V394A, E401G, T426A, K455R, A461P, K(Q)467N, and K497E.
[0041] (N) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: N329K, I366F, V394A, E401G, T426A, K455R, A461P, K(Q)467N, and V499I.
[0042] (O) An AAV binding protein comprising amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, and in which at least the following amino acid substitutions have occurred in the amino acid residues at positions 25 to 213: G314D, N329K, I366F, V394A, E401G, T426A, K455R, A461P, K(Q)467N, K497E, and V499I.
[0043] In (ii) and (v) above, "one or several" will vary depending on the position of the amino acid substitution in the three-dimensional structure of the AAV-binding protein and the type of amino acid residue, but, for example, means any of 1 to 50, 1 to 40, 1 to 30, 1 to 25, 1 to 20, 1 to 18, 1 to 15, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1.
[0044] Examples of the substitutions, deletions, insertions, or additions described in (ii) and (v) above include the amino acid residue substitutions disclosed in WO2021 / 106882 and WO2023 / 140197.
[0045] The "substitution of one or several amino acid residues" in (ii) and (v) above may include, in addition to the amino acid substitution at the specific position described above, conservative substitutions in which amino acids with similar physical and / or chemical properties are substituted. Conservative substitutions are generally known to those skilled in the art to maintain protein function between substituted and unsubstituted amino acids. Examples of conservative substitutions include substitutions between glycine and alanine, between serine and threonine, or between glutamic acid and aspartic acid (Protein Structure and Function, Medical Science International, 9, 2005). Another example of the amino acid substitution is a substitution for monomerizing an AAV-binding protein. Specifically, an amino acid substitution in which a cysteine residue, which is likely to form a higher-order structure, is replaced with a serine or methionine residue is used.
[0046] Furthermore, the "substitution, deletion, insertion, or addition of one or several amino acid residues" in (ii) and (v) above also includes naturally occurring mutations (mutants or variants) based on differences in the origin or species of the AAV binding protein.
[0047] The identity of the amino acid sequences in (iii) and (vi) may be 70% or more, and may be higher (e.g., 80% or more, 85% or more, 90% or more, or 95% or more). "Amino acid sequence identity" refers to identity with respect to the entire amino acid sequence. "Identity" between amino acid sequences refers to the ratio of amino acid residues in those amino acid sequences that have the same type of amino acid (Experimental Medicine, 31(3), Yodosha). The identity of amino acid sequences can be determined using alignment programs such as BLAST (Basic Local Alignment Search Tool) and FASTA.
[0048] The present disclosure provides a method for purifying AAV contained in a sample using an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the carrier (hereinafter also referred to as an "AAV adsorbent"). The AAV-binding protein is not particularly limited as long as it is a polypeptide capable of binding to AAV, and examples thereof include laminin receptors such as integrins, anti-AAV antibodies, and AAV receptors (AAVRs).
[0049] When the AAV-binding protein is an anti-AAV antibody, a preferred embodiment is a polypeptide comprising at least a heavy chain antibody variable region (VHH) capable of binding to AAV. When the AAV-binding protein is an AAVR, a preferred embodiment is a polypeptide selected from any of the following to <iii>: a polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO: 1; <ii> a polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid residues from positions 312 to 500 have undergone one or more of the following substitutions, deletions, insertions and additions of one or several amino acid residues at one or several positions, and which has AAV-binding activity; <iii> a polypeptide comprising at least the amino acid residues from serine at position 312 to aspartic acid at position 500 in the amino acid sequence set forth in SEQ ID NO: 1, provided that the amino acid sequence has an identity of 70% or more to the entire amino acid sequence consisting of the amino acid residues from positions 312 to 500, and which has AAV-binding activity.
[0050] The amino acid sequence set forth in SEQ ID NO: 1 is the amino acid sequence of KIAA0319L (official database: UniProt, accession number: Q8IZA0), which is one embodiment of AAVR, and the amino acid residues from serine (S) at position 312 to aspartic acid (D) at position 500 in the amino acid sequence set forth in SEQ ID NO: 1 correspond to the extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L.
[0051] The polypeptides described in any of to <iii> above need only contain at least the regions corresponding to the PKD1 and PKD2 of the above-mentioned KIAA0319L, and may, for example, contain all or part of the regions corresponding to other extracellular region domains (domain 3 (PKD3), domain 4 (PKD4), and domain 5 (PKD5)) located on the C-terminal side of PKD2, or may contain all or part of a region corresponding to a signal sequence or cysteine-rich region such as the MANSC (Motif At N terminus with Seven Cysteines) domain located on the N-terminal side of PKD1, or may contain all or part of a transmembrane region and an intracellular region located on the N-terminal and / or C-terminal side of the extracellular region.
[0052] Examples of <ii> include the AAV-binding proteins disclosed in WO2021 / 106882 and WO2023 / 140197, and AAV-binding proteins having at least one amino acid substitution shown in (I) to (LXIX) below: (I) substitution of glycine at position 314 in SEQ ID NO: 1 with aspartic acid; (II) substitution of valine at position 317 in SEQ ID NO: 1 with glycine; (III) substitution of glutamine at position 318 in SEQ ID NO: 1 with arginine; (IV) substitution of isoleucine at position 319 in SEQ ID NO: 1 with asparagine; (V) substitution of leucine at position 321 in SEQ ID NO: 1 with glutamine; (VI) substitution of proline at position 322 in SEQ ID NO: 1 with alanine; (VII) substitution of glutamic acid at position 325 in SEQ ID NO: 1 with valine; and (VIII) substitution of leucine at position 328 in SEQ ID NO: 1 with proline. (IX) Asparagine at position 329 of SEQ ID NO: 1 is replaced by lysine or serine. (X) Valine at position 332 of SEQ ID NO: 1 is replaced by alanine. (XI) Glutamic acid at position 335 of SEQ ID NO: 1 is replaced by alanine. (XII) Lysine at position 338 of SEQ ID NO: 1 is replaced by arginine. (XIII) Glutamic acid at position 340 of SEQ ID NO: 1 is replaced by glycine. (XIV) Threonine at position 343 of SEQ ID NO: 1 is replaced by alanine or serine. (XV) Tyrosine at position 344 of SEQ ID NO: 1 is replaced by phenylalanine. (XVI) Aspartic acid at position 345 of SEQ ID NO: 1 is replaced by glycine. (XVII) Glutamine at position 347 of SEQ ID NO: 1 is replaced by lysine or arginine. (XVIII) Threonine at position 350 of SEQ ID NO: 1 is replaced by alanine. (XIX) Glutamic acid at position 360 of SEQ ID NO: 1 is replaced by aspartic acid. (XX) Lysine at position 362 in SEQ ID NO: 1 is substituted with aspartic acid. (XXI) Histidine at position 363 in SEQ ID NO: 1 is substituted with proline. (XXII) Glutamine at position 365 in SEQ ID NO: 1 is substituted with arginine. (XXIII) Isoleucine at position 366 in SEQ ID NO: 1 is substituted with phenylalanine. (XXIV) Leucine at position 367 in SEQ ID NO: 1 is substituted with proline. (XXV) Lysine at position 368 in SEQ ID NO: 1 is substituted with arginine. (XXVI) Leucine at position 369 in SEQ ID NO: 1 is substituted with serine. (XXVII) Lysine at position 371 in SEQ ID NO: 1 is substituted with aspartic acid or serine.(XXVIII) Leucine at position 376 in SEQ ID NO: 1 is replaced with proline. (XXIX) Tyrosine at position 377 in SEQ ID NO: 1 is replaced with phenylalanine or asparagine. (XXX) Glutamic acid at position 378 in SEQ ID NO: 1 is replaced with glycine. (XXXI) Phenylalanine at position 379 in SEQ ID NO: 1 is replaced with serine or asparagine. (XXXII) Valine at position 381 in SEQ ID NO: 1 is replaced with threonine. (XXXIII) Glutamic acid at position 384 in SEQ ID NO: 1 is replaced with aspartic acid. (XXXIV) Histidine at position 389 in SEQ ID NO: 1 is replaced with arginine. (XXXV) Glycine at position 392 in SEQ ID NO: 1 is replaced with glutamic acid. (XXXVI) Valine at position 394 in SEQ ID NO: 1 is replaced with alanine or isoleucine. (XXXVII) Valine at position 396 in SEQ ID NO: 1 is replaced with glutamic acid. (XXXVIII) Threonine at position 397 of SEQ ID NO: 1 is replaced by alanine or serine. (XXXIV) Valine at position 398 of SEQ ID NO: 1 is replaced by alanine. (XL) Glutamic acid at position 401 of SEQ ID NO: 1 is replaced by glycine. (XLI) Proline at position 402 of SEQ ID NO: 1 is replaced by serine. (XLII) Arginine at position 406 of SEQ ID NO: 1 is replaced by histidine. (XLIII) Valine at position 412 of SEQ ID NO: 1 is replaced by alanine. (XLIV) Glutamine at position 415 of SEQ ID NO: 1 is replaced by arginine. (XLV) Phenylalanine at position 416 of SEQ ID NO: 1 is replaced by leucine. (XLVI) Leucine at position 421 of SEQ ID NO: 1 is replaced by proline. (XLVII) Threonine at position 426 of SEQ ID NO: 1 is replaced by alanine. (XLVIII) Serine at position 433 of SEQ ID NO: 1 is replaced by glycine. (XLIX) Threonine at position 434 in SEQ ID NO: 1 is replaced with serine. (L) Aspartic acid at position 435 in SEQ ID NO: 1 is replaced with alanine. (LI) Aspartic acid at position 437 in SEQ ID NO: 1 is replaced with valine. (LII) Glutamic acid at position 445 in SEQ ID NO: 1 is replaced with lysine. (LIII) Glutamic acid at position 453 in SEQ ID NO: 1 is replaced with aspartic acid. (LIV) Glutamic acid at position 454 in SEQ ID NO: 1 is replaced with aspartic acid. (LV) Lysine at position 455 in SEQ ID NO: 1 is replaced with arginine. (LVI) Serine at position 457 in SEQ ID NO: 1 is replaced with arginine.(LVII) Alanine at position 461 in SEQ ID NO: 1 is replaced with proline. (LVIII) Serine at position 466 in SEQ ID NO: 1 is replaced with threonine. (LIX) Lysine at position 467 in SEQ ID NO: 1 is replaced with asparagine. (LX) Asparagine at position 472 in SEQ ID NO: 1 is replaced with lysine. (LXI) Threonine at position 474 in SEQ ID NO: 1 is replaced with arginine. (LXII) Threonine at position 478 in SEQ ID NO: 1 is replaced with isoleucine. (LXIII) Alanine at position 485 in SEQ ID NO: 1 is replaced with valine. (LXIV) Threonine at position 486 in SEQ ID NO: 1 is replaced with alanine. (LXV) Leucine at position 493 in SEQ ID NO: 1 is replaced with methionine. (LXVI) Asparagine at position 496 in SEQ ID NO: 1 is replaced with glutamic acid. (LXVII) Lysine at position 497 in SEQ ID NO: 1 is replaced with glutamic acid. (LXVIII) Valine at position 499 of SEQ ID NO: 1 is replaced with isoleucine. (LXIX) Aspartic acid at position 500 of SEQ ID NO: 1 is replaced with glycine or asparagine. Examples of the substitution, deletion, insertion, or addition described in <ii> above include the amino acid substitutions disclosed in WO2021 / 106882 and WO2023 / 140197, and the amino acid substitutions shown in (I) to (LXIX) above.
[0053] In the above <ii>, "one or several" varies depending on the position of the amino acid substitution in the three-dimensional structure of AAVR and the type of amino acid residue, but for example, it means 1 to 50 or less, 1 to 40 or less, 1 to 30 or less, 1 to 25 or less, 1 to 20 or less, 1 to 15 or less, 1 to 10 or less, 1 to 9 or less, 1 to 8 or less, 1 to 7 or less, 1 to 6 or less, 1 to 5 or less, 1 to 4 or less, 1 to 3 or less, 1 to 2 or less, or 1. The substitution of "one or several" amino acid residues may occur at positions other than the amino acid residue substitutions disclosed in WO2021 / 106882 and WO2023 / 140197, and the amino acid residue substitutions shown in (I) to (LXIX), as long as they have AAV binding activity.
[0054] The "substitution of one or several amino acid residues" in <ii> above may include, in addition to the amino acid substitution at the specific position described above, conservative substitutions in which amino acids with similar physical and / or chemical properties are substituted. Conservative substitutions are generally known to those skilled in the art to maintain protein function between substituted and unsubstituted amino acids. Examples of conservative substitutions include substitutions between glycine and alanine, between serine and threonine, or between glutamic acid and aspartic acid (Protein Structure and Function, Medical Science International, 9, 2005). Furthermore, the "substitution, deletion, insertion, or addition of one or several amino acid residues" in <ii> above also includes naturally occurring mutations (mutants or variants) based on differences in the origin of AAVR, differences in species, etc.
[0055] The identity of the amino acid sequences in <iii> may be 70% or more, and may be higher (e.g., 80% or more, 85% or more, 90% or more, or 95% or more). The "identity" between amino acid sequences refers to the ratio of amino acid residues of the same type in those amino acid sequences (Experimental Medicine, 31(3), Yodosha). The identity of amino acid sequences can be determined using alignment programs such as BLAST (Basic Local Alignment Search Tool) and FASTA.
[0056] In one embodiment, the AAV-binding protein of the present disclosure may further have an oligopeptide attached to its N-terminus or C-terminus that is useful for separating the protein from a solution in the presence of contaminants. Examples of such oligopeptides include polyhistidine, polylysine, polyarginine, polyglutamic acid, polyaspartic acid, etc. Furthermore, a cysteine-containing oligopeptide that is useful for immobilizing the AAV-binding protein on a solid phase such as a chromatographic support may further be attached to the N-terminus or C-terminus of the AAV-binding protein.
[0057] The length of the oligopeptide added to the N- or C-terminus of the AAV binding protein is not particularly limited, as long as it does not impair the AAV-binding ability or stability of the AAV binding protein. When adding the oligopeptide to the AAV binding protein of the present disclosure, a polynucleotide encoding the oligopeptide may be prepared, and then the oligopeptide may be added to the N- or C-terminus of the AAV binding protein by genetic engineering using methods well known to those skilled in the art. Alternatively, the chemically synthesized oligopeptide may be chemically bonded to the N- or C-terminus of the AAV binding protein.
[0058] Furthermore, a signal peptide may be added to the N-terminus of the AAV binding protein of the present disclosure to promote efficient expression in Escherichia coli used as a host. Examples of such signal peptides include signal peptides that cause proteins to be secreted into the periplasm, such as PelB, OmpA, DsbA, DsbC, MalE, and TorT (Japanese Patent Application Laid-Open No. 2011-097898). Addition of a signal peptide to the N-terminus is also not necessary. This is preferable in that protein homogeneity is improved during protein preparation.
[0059] Examples of methods for producing a polynucleotide encoding an AAV-binding protein of the present disclosure (hereinafter also referred to as "polynucleotide of the present disclosure") include: (I) a method of converting the amino acid sequence of the AAV-binding protein of the present disclosure into a nucleotide sequence and artificially synthesizing a polynucleotide containing the nucleotide sequence; and (II) a method of preparing a polynucleotide containing the entire or partial sequence of the AAV-binding protein artificially directly, or by using a DNA amplification method such as PCR from the cDNA of the AAV-binding protein, and then ligating the prepared polynucleotides by an appropriate method.
[0060] In the method (I), when converting an amino acid sequence to a nucleotide sequence, it is preferable to consider the codon usage frequency in the host E. coli to be transformed. Specifically, AGA / AGG / CGG / CGA for arginine (R), ATA for isoleucine (I), CTA for leucine (L), GGA for glycine (G), and CCC for proline (P) are used infrequently (so-called rare codons), so conversion can be performed to avoid these codons. Analysis of codon usage frequency can also be performed using public databases (e.g., the Codon Usage Database on the Kazusa DNA Research Institute website).
[0061] When introducing a mutation into the polynucleotide of the present disclosure, an error-prone PCR method can be used. The reaction conditions for the error-prone PCR method are not particularly limited as long as they allow the introduction of a desired mutation into the polynucleotide encoding the AAV binding protein. For example, the concentrations of the four types of substrate deoxynucleotides (dATP / dTTP / dCTP / dGTP) are made uneven, and MnCl 2 A mutation can be introduced into a polynucleotide by adding the above to a PCR reaction solution at a concentration of 0.01 mM to 10 mM (preferably 0.1 mM to 1 mM) and performing PCR. Mutations other than error-prone PCR include methods of introducing mutations into a polynucleotide by contacting or reacting a polynucleotide containing the entire or partial sequence of an AAV binding protein with a mutagenic agent or by irradiating it with ultraviolet light. The mutagen used in this method may be any mutagenic agent commonly used by those skilled in the art, such as hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine, nitrous acid, sulfurous acid, or hydrazine.
[0062] When transforming a host, Escherichia coli, with a polynucleotide of the present disclosure, the polynucleotide of the present disclosure may be used as is, but it is more preferable to use an expression vector (e.g., a bacteriophage, cosmid, or plasmid typically used for transforming prokaryotic or eukaryotic cells) into which the polynucleotide of the present disclosure has been inserted at an appropriate position. The expression vector is not particularly limited as long as it can stably exist and replicate in the host (Escherichia coli) to be transformed, and examples thereof include pET plasmid vector, pUC plasmid vector, pTrc plasmid vector, and pCDF plasmid vector.
[0063] The appropriate position may mean a position that does not disrupt the replication function of the expression vector, the desired antibiotic marker, or regions involved in transduction. When inserting the polynucleotide of the present disclosure into the expression vector, it is preferable to insert it in a state linked to a functional polynucleotide, such as a promoter required for expression. Examples of such promoters include the trp promoter, tac promoter, trc promoter, lac promoter, T7 promoter, recA promoter, and lpp promoter.
[0064] The host Escherichia coli can be transformed with an expression vector containing a polynucleotide of the present disclosure inserted therein, prepared by the above-described method (hereinafter also simply referred to as "the expression vector of the present disclosure"), using a method commonly used by those skilled in the art. Specifically, transformation can be performed by a method described in known publications such as Molecular Cloning (Cold Spring Harbor Laboratory), 256, 1992. Transformants obtained by transformation using the above-described method can be screened by an appropriate method to obtain a transformant capable of expressing the AAV-binding protein of the present disclosure (hereinafter also simply referred to as "the transformant of the present disclosure").
[0065] To prepare an expression vector of the present disclosure from a transformant of the present disclosure, the vector may be prepared from a culture obtained by culturing the transformant of the present disclosure by alkaline extraction or using a commercially available extraction kit such as the QIAprep Spin Miniprep kit (manufactured by Qiagen).
[0066] The AAV-binding protein of the present disclosure can be produced by culturing the transformant of the present disclosure and recovering the AAV-binding protein of the present disclosure from the resulting culture. Note that, as used herein, the culture may include not only the cultured cells of the transformant of the present disclosure themselves, but also the medium used for the culture.
[0067] The transformant used in the protein production method may be cultured in a medium suitable for culturing the target host (Escherichia coli), and a preferred example of the medium is Luria-Bertani (LB) medium supplemented with necessary nutrients. To selectively grow transformants depending on whether or not a vector of the present disclosure has been introduced, it is preferable to culture the transformant in a medium supplemented with a drug corresponding to the drug resistance gene contained in the vector. For example, if the vector contains a kanamycin resistance gene, kanamycin can be added to the medium.
[0068] In addition to carbon, nitrogen, and inorganic salt sources, the medium may contain appropriate nutrient sources and, if desired, one or more reducing agents selected from the group consisting of glutathione, cysteine, cystamine, thioglycolate, and dithiothreitol. The culture temperature is generally 10°C to 40°C, preferably 20°C to 37°C, and more preferably around 25°C, but may be selected depending on the properties of the protein to be expressed. The pH of the medium is 6.8 to 7.4, preferably around 7.0. Furthermore, when the vector of the present disclosure contains an inducible promoter, it is preferable to induce the promoter under conditions that allow good expression of the AAV binding protein of the present disclosure.
[0069] An example of an inducer is IPTG (isopropyl-β-D-thiogalactopyranoside). The turbidity of the culture solution (absorbance at 600 nm) is measured, and when it reaches approximately 0.5 to 1.0, an appropriate amount of IPTG is added, followed by continued cultivation, thereby inducing expression of the AAV binding protein. The concentration of IPTG added may be appropriately selected from the range of 0.005 mM to 1.0 mM, with the range of 0.01 mM to 0.5 mM being preferred. IPTG induction may be carried out under various conditions well known in the art.
[0070] To recover the AAV-binding protein of the present disclosure from a culture obtained by culturing a transformant of the present disclosure, the AAV-binding protein may be recovered by separating / purifying it from the culture using a method suitable for the expression form of the AAV-binding protein in the transformant. For example, when the protein is expressed in the culture supernatant, the bacterial cells may be separated by centrifugation, and the AAV-binding protein may be purified from the resulting culture supernatant. When the protein is expressed intracellularly (which may include the periplasm), the bacterial cells may be collected by centrifugation, disrupted by adding an enzyme treatment agent, a surfactant, or the like, and the AAV-binding protein may be extracted and then purified.
[0071] The AAV-binding protein of the present disclosure can be purified using methods known in the art, such as separation / purification using liquid chromatography. Examples of liquid chromatography include ion exchange chromatography, hydrophobic interaction chromatography, gel filtration chromatography, and affinity chromatography. By combining these chromatographic methods for purification, the AAV-binding protein of the present disclosure can be prepared with high purity.
[0072] The binding activity of the obtained AAV-binding protein of the present disclosure to AAV can be measured, for example, by enzyme-linked immunosorbent assay (hereinafter referred to as ELISA). The AAV used to measure binding activity may be a VLP (virus-like particle). Furthermore, any serotype (serotype) of AAV vector and VLP may be used as long as they exhibit binding activity to the AAV-binding protein of the present disclosure.
[0073] The AAV-binding protein of the present disclosure can be used, for example, for purifying or analyzing AAV. When used for this purpose, the AAV to be bound is not particularly limited, and may be a naturally occurring AAV or an artificially produced AAV. Examples of naturally occurring AAV include serotype 1 (AAV1), serotype 2 (AAV2), serotype 3 (AAV3), serotype 4 (AAV4), serotype 5 (AAV5), serotype 6 (AAV6), serotype 7 (AAV7), serotype 8 (AAV8), serotype 9 (AAV9), serotype 10 (AAV10), serotype 11 (AAV11), serotype 12 (AAV12), and serotype 13 (AAV13). Artificially produced AAVs include AAVrh8, AAVrhlO, and chimeric AAVs having characteristics (cell tropism and infectivity) of two or more of these serotypes.
[0074] The AAV binding protein of the present disclosure can be used, for example, by immobilizing on an insoluble carrier.That is, specifically, the purification or analysis of AAV can be carried out using an AAV adsorbent, which comprises, for example, an insoluble carrier and the AAV binding protein of the present disclosure immobilized on this insoluble carrier.In this specification, the AAV adsorbent, which comprises, for example, an insoluble carrier and the AAV binding protein of the present disclosure immobilized on this insoluble carrier, is also referred to as the AAV adsorbent of the present disclosure.It should be noted that the purification of AAV is not limited to the purification of AAV from a solution containing contaminants, but also includes the purification of AAV based on structure, properties, activity, etc.
[0075] The insoluble carrier, a component of the AAV adsorbent of the present disclosure, is not particularly limited as long as it is insoluble in AAV-containing samples and solutions used for purification (e.g., elution solutions, equilibration solutions, and wash solutions). Examples of insoluble carriers include carriers made from polysaccharides such as agarose, alginate (alginate salts), carrageenan, chitin, cellulose, dextrin, dextran, and starch; carriers made from synthetic polymers such as polyvinyl alcohol, polymethacrylate, poly(2-hydroxyethyl methacrylate), and polyurethane; and carriers made from ceramics such as silica. Among these, carriers made from polysaccharides and carriers made from synthetic polymers are preferred as insoluble carriers. Examples of preferred carriers include polymethacrylate gels with introduced hydroxy groups, such as Toyopearl (manufactured by Tosoh Corporation), agarose gels such as Sepharose (manufactured by Cytiva Corporation), and cellulose gels such as Cellufine (manufactured by JNC Corporation). The shape of the insoluble carrier is not particularly limited, and may be, for example, granular, monolithic, membrane-like, or fibrous, and may be either porous or non-porous. Among these, a shape that can be packed into a column is preferred.
[0076] When producing an AAV adsorbent, the AAV-binding protein may be immobilized on an insoluble carrier, for example, via a covalent bond. Specifically, for example, the AAV-binding protein may be immobilized on the insoluble carrier by covalently bonding the insoluble carrier via an active group possessed by the insoluble carrier, thereby producing an AAV adsorbent. Examples of the active group include an N-hydroxysuccinimide (NHS)-activated ester group, an epoxy group, a carboxy group, a maleimide group, a haloacetyl group, a tresyl group, a formyl group, and a haloacetamide group. As the insoluble carrier having an active group, for example, a commercially available insoluble carrier having an active group may be used as is, or an active group may be introduced into the insoluble carrier. Examples of commercially available carriers having an active group include TOYOPEARL AF-Epoxy-650M and TOYOPEARL AF-Tresyl-650M (both manufactured by Tosoh Corporation), HiTrap NHS-activated HP Columns, NHS-activated Sepharose 4 Fast Flow, and Epoxy-activated Sepharose 6B (all manufactured by Cytiva Corporation), and SulfoLink Coupling Resin (manufactured by Thermo Fisher Scientific).
[0077] An example of a method for introducing active groups onto the support surface is a method in which one of a compound having two or more active sites is reacted with a hydroxy group, epoxy group, carboxy group, amino group, etc. present on the support surface.
[0078] Examples of compounds that introduce epoxy groups into hydroxy groups or amino groups present on the surface of a carrier include epichlorohydrin, ethanediol diglycidyl ether, butanediol diglycidyl ether, and hexanediol diglycidyl ether.
[0079] Examples of compounds that introduce carboxy groups into epoxy groups present on the surface of the carrier include 2-mercaptoacetic acid, 3-mercaptopropionic acid, 4-mercaptobutyric acid, 6-mercaptobutyric acid, glycine, 3-aminopropionic acid, 4-aminobutyric acid, and 6-aminohexanoic acid.
[0080] Furthermore, examples of compounds that introduce maleimide groups into hydroxy groups, epoxy groups, carboxy groups, and amino groups present on the surface of a carrier include N-(ε-maleimidocaproic acid) hydrazide, N-(ε-maleimidopropionic acid) hydrazide, 4-(4-N-maleimidophenyl)acetic acid hydrazide, 2-aminomaleimide, 3-aminomaleimide, 4-aminomaleimide, 6-aminomaleimide, 1-(4-aminophenyl)maleimide, 1-(3-aminophenyl)maleimide, 4-(maleimido)phenyl isocyanate, 2-maleimidoacetic acid, 3-maleimidopropionic acid, and the like. Examples include pionic acid, 4-maleimidobutyric acid, 6-maleimidohexanoic acid, N-(α-maleimidoacetoxy)succinimide ester, (m-maleimidobenzoyl)N-hydroxysuccinimide ester, succinimidyl-4-(maleimidomethyl)cyclohexane-1-carbonyl-(6-aminohexanoic acid), succinimidyl-4-(maleimidomethyl)cyclohexane-1-carboxylic acid, (p-maleimidobenzoyl)N-hydroxysuccinimide ester, and (m-maleimidobenzoyl)N-hydroxysuccinimide ester.
[0081] Furthermore, examples of compounds that introduce haloacetyl groups into hydroxy groups or amino groups present on the surface of a carrier include chloroacetic acid, bromoacetic acid, iodoacetic acid, chloroacetic acid chloride, bromoacetic acid chloride, bromoacetic acid bromide, chloroacetic acid anhydride, bromoacetic acid anhydride, iodoacetic acid anhydride, 2-(iodoacetamido)acetic acid-N-hydroxysuccinimide ester, 3-(bromoacetamido)propionic acid-N-hydroxysuccinimide ester, and 4-(iodoacetyl)aminobenzoic acid-N-hydroxysuccinimide ester.
[0082] Another example of a method for introducing active groups onto the support surface is to react an ω-alkenylalkane glycidyl ether with a hydroxy group or amino group present on the support surface, followed by activation by halogenating the ω-alkenyl moiety with a halogenating agent. Examples of ω-alkenylalkane glycidyl ethers include allyl glycidyl ether, 3-butenyl glycidyl ether, and 4-pentenyl glycidyl ether. Examples of halogenating agents include N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide.
[0083] Another example of a method for introducing active groups onto the support surface is a method in which active groups are introduced onto carboxy groups present on the support surface using a condensing agent and an additive. Examples of condensing agents include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), dicyclohexylcarbodiamide, and carbonyldiimidazole. Examples of additives include NHS, 4-nitrophenol, and 1-hydroxybenztriazole.
[0084] Immobilization of an AAV-binding protein to an insoluble carrier can be carried out, for example, in a buffer solution. Examples of buffer solutions include acetate buffer, phosphate buffer, MES (2-morpholinoethane sulfonic acid) buffer, HEPES (4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid) buffer, Tris (Tris(hydroxymethyl)aminomethane) buffer, and borate buffer. The reaction temperature during immobilization can be appropriately set depending on various conditions, such as the reactivity of the active group and the stability of the AAV-binding protein. The reaction temperature during immobilization may be, for example, 4°C or higher and 50°C or lower, and preferably 10°C or higher and 35°C or lower.
[0085] The AAV adsorbent of the present disclosure can be packed into a column and used for purifying or analyzing AAV, for example. Specifically, for example, AAV can be purified or analyzed by adding a solution containing AAV to a column packed with the AAV adsorbent of the present disclosure (hereinafter also referred to simply as the "column of the present disclosure") to adsorb the AAV to the adsorbent, and then eluting the AAV adsorbed to the adsorbent. That is, in one aspect, the present disclosure provides a method for purifying or analyzing AAV, comprising the steps of adding a solution containing AAV to a column of the present disclosure to adsorb the AAV to the adsorbent, and eluting the AAV adsorbed to the adsorbent. AAV purification using a column of the present disclosure may be carried out, for example, based on the disclosures in WO2021 / 106882.
[0086] Purifying AAV using the AAV adsorbent of the present disclosure can yield purified AAV. That is, in one embodiment, the method for purifying AAV may be a method for producing AAV, specifically, a method for producing purified AAV. AAV is obtained, for example, as an elution fraction containing AAV. That is, a fraction containing eluted AAV can be separated and collected. Separation of AAV fractions can be performed, for example, by conventional methods. Methods for separating AAV fractions include replacing the collection container at regular intervals or at regular volumes, changing the collection container according to the shape of the chromatogram of the eluate, and separating fractions using an automatic fraction collector such as an autosampler. Furthermore, AAV can also be recovered from the fraction containing AAV. Recovering AAV from the fraction containing AAV can be performed, for example, by known methods used for protein purification.
[0087] By washing the AAV adsorbent of the present disclosure with an alkali, it is possible to prevent, for example, the incorporation of remaining AAV or impurities. That is, in one embodiment, the method for washing the AAV adsorbent may be a method for washing the AAV adsorbent with an alkali, which is carried out after purifying AAV. Furthermore, since the AAV-binding protein of the present disclosure is also acid-resistant, the method may involve washing with a low pH solution followed by alkali washing. An example of the alkaline solution used for washing is a 0.1 M to 0.5 M aqueous sodium hydroxide solution.
[0088] In one aspect, the method for purifying AAV of the present disclosure may mean purifying an AAV vector containing a gene (full AAV vector).
[0089] In one aspect, the method for purifying AAV of the present disclosure comprises the steps of: adding a sample containing AAV to an AAV adsorbent and adsorbing the AAV to the adsorbent (hereinafter also referred to as the "first adsorption step"); eluting the AAV adsorbed to the adsorbent (hereinafter also referred to as the "first elution step"); adding a fraction containing the AAV eluted in the first elution step to an anion exchange chromatography carrier and adsorbing the AAV to the carrier (hereinafter also referred to as the "second adsorption step"); and eluting the AAV adsorbed to the anion exchange chromatography carrier (hereinafter also referred to as the "second elution step"). Note that a mode in which the AAV adsorbent and the anion exchange chromatography carrier are packed in a column (hereinafter also referred to as the "AAV adsorbent column" and the "anion exchange column," respectively) is preferred in that these steps can be carried out easily. Below, a detailed description will be given using an AAV adsorbent column and an anion exchange column as examples.
[0090] A sample containing AAV can be added to the AAV adsorbent column using a liquid delivery means such as a pump. In this specification, adding a liquid to a column is also referred to as "delivering a liquid to the column." The AAV-containing sample may be solvent-substituted with an appropriate buffer solution before being added to the AAV adsorbent column. Furthermore, before adding the AAV-containing sample to the AAV adsorbent column (i.e., before the first adsorption step), the AAV adsorbent column may be equilibrated with an appropriate buffer solution (equilibration solution). This equilibration is expected to enable, for example, the purification of AAV with higher purity. The buffer used for solvent substitution or equilibration may be a neutral buffer having buffering capacity in the neutral range (herein referring to a pH range of 5.0 to 9.0, preferably 5.5 to 8.0). Specific examples include phosphate buffer, acetate buffer, succinate buffer, citrate buffer, Tris buffer, HEPES buffer, and MES buffer. Such a buffer solution may further contain, for example, 0.1 mmol / L to 50 mmol / L of a chelating agent. The buffer solution used for solvent substitution and the equilibration solution may or may not be the same.
[0091] Furthermore, if components other than AAV, such as impurities, remain in the AAV adsorbent column after passing an AAV-containing sample through the AAV adsorbent column, such components may be removed (washed) from the AAV adsorbent column before eluting the AAV adsorbed to the AAV adsorbent (i.e., before the elution step). Components other than AAV can be removed from the AAV adsorbent column, for example, by using an appropriate buffer solution as a wash solution. For example, the descriptions regarding buffer solutions used for solvent substitution and equilibration can be applied mutatis mutandis to the wash solution.
[0092] In one embodiment, in the first elution step, the AAV adsorbed to the AAV adsorbent in the first adsorption step may be eluted using, for example, a buffer solution having a lower pH than the equilibration solution or the wash solution, a neutral buffer solution containing 800 mmol / L or more of chloride ions or anions smaller in the Hofmeister series than said ions, or a buffer solution containing a chelating agent (e.g., ethylenediaminetetraacetic acid) adjusted to the pH used in the second adsorption step. By passing the eluate through an AAV adsorbent column, the interaction between AAV and AAV-binding proteins (ligands of the AAV adsorbent) in the column is weakened, and the AAV adsorbed to the AAV adsorbent is eluted, thereby obtaining a fraction containing AAV.
[0093] The AAV-containing fraction obtained in the first elution step may be adjusted to a pH of about 8.0 to 9.5 using Tris, for example, or diluted with the buffer used in the second adsorption step.
[0094] The anion exchange column can be produced, for example, by immersing an anion exchange chromatography support in a 1 mol / L aqueous sodium chloride solution and then packing the column. The buffer component used in the second adsorption step and the second elution step may be any buffer component having a buffer capacity in the range of pH 8.0 to 9.5, preferably Tris.
[0095] In one embodiment, preferred examples of salts to be contained in the eluate in the second elution step include sodium chloride, sodium acetate, ammonium chloride, ammonium acetate, tetramethylammonium chloride, magnesium chloride, calcium chloride, ammonium sulfate, tetraethylammonium chloride, choline chloride, acetylcholine chloride, carnitine hydrochloride, trimethylglycine, etc., and more preferred are tetraethylammonium chloride and choline chloride. In particular, the inclusion of choline chloride in the eluate is preferred because it enables the purification of infectious full AAV with high purity. Full AAV may refer to AAV containing a gene.
[0096] In the second elution step, for example, the salt concentration is increased to an appropriate concentration using a linear gradient to elute a first peak, and then the salt concentration is increased using a step gradient to elute a second peak. For example, when AAV8 is used, a fraction containing a high proportion of empty AAV is obtained in the first peak, and a fraction containing a high proportion of full AAV is obtained in the second peak.
[0097] In one embodiment, the conductivity of the eluate when eluting the first peak is 13.5 mS / cm or less and the conductivity of the eluate when eluting the second peak is 15.0 mS / cm or more is preferred because it increases the proportion of full AAV contained in the second peak. It is even more preferred that the conductivity of the eluate when eluting the first peak is 5.0 mS / cm or more and 13.5 mS / cm or less and the conductivity of the eluate when eluting the second peak is 15.0 mS / cm or more and 50.0 mS / cm or less. It is even more preferred that the conductivity of the eluate when eluting the first peak is 12.0 mS / cm or more and 13.5 mS / cm or less and the conductivity of the eluate when eluting the second peak is 20.0 mS / cm or more and 40.0 mS / cm or less. The conductivity can be measured using a conductivity monitor built into a liquid chromatography system such as AKTA go (manufactured by Cytiva).
[0098] Herein, the percentage of AAV vectors containing a gene is also referred to as the “full rate.” The full rate can be measured by mass photometry, such as with Refeyn Two (manufactured by Refeyn).
[0099] The present disclosure will be described in more detail below using examples and reference examples, but the present disclosure is not limited to these examples. Note that the reference examples do not constitute the present disclosure.
[0100] Example 1: Preparation of AAV Vector (Part 1) (1) The Escherichia coli JM109 strain was transformed with the pRC2-mi342 Vector (Takara Bio Inc.) and pHelper Vector (Takara Bio Inc.), plasmids containing a polynucleotide encoding the capsid of AAV serotype 2 (AAV2). The resulting transformants were cultured overnight at 37°C with shaking in a 5-L baffled flask containing 1 L of 2xYT medium (1.6% (w / v) Tryptone, 1% (w / v) Yeast Extract, 0.5% (w / v) sodium chloride) containing 100 μg / mL carbenicillin.
[0101] (2) The culture medium of (1) was centrifuged to collect the bacterial cells, and then the pRC2-mi342 Vector and pHelper Vector were prepared in large quantities from the collected bacterial cells using Plasmid Mega Kit (Qiagen).
[0102] (3) HEK293T cells were cultured in five T-225 flasks (manufactured by Thermo Fisher Scientific) containing 40 mL of D-MEM medium (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) containing 10% (v / v) bovine serum.
[0103] (4) Using TransIT-ViruGEN Transfection Reagent (manufactured by Takara Bio Inc.), the pRC2-mi342 Vector and pHelper Vector prepared in (2) were transfected into the HEK293T cells cultured in (3), and the cells were statically cultured under conditions of 5% carbon dioxide and 37°C for 3 days.
[0104] (5) The cells cultured in (4) were collected and extracted and purified using an AAVpro Purification Kit (Takara Bio Inc.) to obtain VLP2 (virus-like particles, outer capsid protein particles of AAV serotype 2). Approximately 1 mL of purified VLP2 solution was prepared from five T-225 flasks.
[0105] Example 2: Preparation and Screening of AAV-binding Protein Mutation Library (Part 1) Using the vector pET-AVR21 capable of expressing a polypeptide containing the AAV-binding protein AVR21 (SEQ ID NO: 2) as a template, random mutations were introduced into the polynucleotide portion encoding the protein by error-prone PCR. In the polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 2, the portion from methionine (M) at position 1 to alanine (A) at position 22 constitutes the PelB signal peptide (the N-terminal 22 amino acid residues of UniProt No. P0C1C1), the portion from serine (S) at position 25 to aspartic acid (D) at position 213 constitutes the AAV-binding protein AVR21, and the histidines (H) at positions 214 to 219 constitute a tag sequence. AVR21 is a polypeptide in which the following 21 amino acid substitutions have been made in the amino acid residues from positions 312 to 500 of SEQ ID NO: 1, which correspond to extracellular domain 1 (PKD1) and domain 2 (PKD2) of the naturally occurring AAV-binding protein KIAA0319L (UniProt No. Q8IZA0) (WO 2023 / 140197).A substitution of valine (V) at position 317 of SEQ ID NO: 1 (position 30 in SEQ ID NO: 2) with aspartic acid (D). A substitution of asparagine (N) at position 324 of SEQ ID NO: 1 (position 37 in SEQ ID NO: 2) with histidine (H). A substitution of valine (V) at position 326 of SEQ ID NO: 1 (position 39 in SEQ ID NO: 2) with alanine (A). A substitution of alanine (A) at position 330 of SEQ ID NO: 1 (position 43 in SEQ ID NO: 2) with valine (V). A substitution of glutamine (Q) at position 334 of SEQ ID NO: 1 (position 47 in SEQ ID NO: 2) with leucine (L). A substitution of glutamic acid (E) at position 335 of SEQ ID NO: 1 (position 48 in SEQ ID NO: 2) with valine (V). A substitution of threonine (T) at position 341 of SEQ ID NO: 1 (position 54 in SEQ ID NO: 2) with alanine (A). Tyrosine (Y) at position 342 of SEQ ID NO: 1 (position 55 in SEQ ID NO: 2) is replaced with serine (S); Lysine (K) at position 362 of SEQ ID NO: 1 (position 75 in SEQ ID NO: 2) is replaced with glutamic acid (E); Lysine (K) at position 371 of SEQ ID NO: 1 (position 84 in SEQ ID NO: 2) is replaced with asparagine (N); Phenylalanine (F) at position 379 of SEQ ID NO: 1 (position 92 in SEQ ID NO: 2) is replaced with tyrosine (Y); Lysine (K) at position 380 of SEQ ID NO: 1 (position 93 in SEQ ID NO: 2) is replaced with arginine (R); Valine (V) at position 381 of SEQ ID NO: 1 (position 94 in SEQ ID NO: 2) is replaced with alanine (A); Isoleucine (I) at position 382 of SEQ ID NO: 1 (position 95 in SEQ ID NO: 2) is replaced with valine (V); Glycine (G) at position 390 of SEQ ID NO: 1 (position 103 in SEQ ID NO: 2) is replaced with serine (S) Lysine (K) at position 399 of SEQ ID NO: 1 (position 112 in SEQ ID NO: 2) is replaced with glutamic acid (E); Lysine (K) at position 467 of SEQ ID NO: 1 (position 180 in SEQ ID NO: 2) is replaced with glutamine (Q); Serine (S) at position 476 of SEQ ID NO: 1 (position 189 in SEQ ID NO: 2) is replaced with arginine (R); Serine (S) at position 482 of SEQ ID NO: 1 (position 195 in SEQ ID NO: 2) is replaced with threonine (T); Asparagine (N) at position 487 of SEQ ID NO: 1 (position 200 in SEQ ID NO: 2) is replaced with aspartic acid (D); Asparagine (N) at position 492 of SEQ ID NO: 1 (position 205 in SEQ ID NO: 2) is replaced with aspartic acid (D).
[0106] (1) Error-prone PCR was performed using, as a template, vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2). Error-prone PCR was performed by preparing a reaction solution having the composition shown in Table 1, heat-treating the reaction solution at 98°C for 2 minutes, and performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 30 seconds, a second step at 55°C for 20 seconds, and a third step at 72°C for 90 seconds, followed by a final heat treatment at 72°C for 5 minutes. The error-prone PCR successfully introduced mutations into the polynucleotide encoding the AAV binding protein, with the average mutation rate being 1.4 amino acid mutations per molecule.
[0107]
[0108] (2) The PCR product obtained in (1) was purified, digested with restriction enzymes NcoI and XhoI, and ligated into the expression vector pET26b (Merck Millipore) that had been pre-digested with the same restriction enzymes.
[0109] (3) After the ligation reaction was completed, Escherichia coli BL21 (DE3) was transformed with the reaction mixture and cultured on a Luria-Bertani (LB) plate medium containing 50 μg / mL kanamycin (at 37°C for 18 hours). The colonies formed on the plate were used as a random mutant library.
[0110] (4) The random mutant library (transformant) prepared in (3) was inoculated into 200 μL of 2YT liquid medium containing 50 μg / mL of kanamycin, and cultured overnight at 37°C with shaking using a 96-well deep-well plate.
[0111] (5) The culture medium from (4) was centrifuged, and the resulting culture supernatant was diluted 2-fold with ultrapure water. 60 μL of the diluted culture medium was mixed with 60 μL of 0.5 M aqueous sodium hydroxide solution and subjected to alkali treatment at 30° C. for 30 minutes.
[0112] (6) The binding activity of the AAV-binding protein to VLP2 when treated with (5) and when not treated with (5) was evaluated by the following enzyme-linked immunosorbent assay (ELISA).
[0113] (6-1) The VLP2 prepared in Example 1 was diluted 200-fold with 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride, and added to a 96-well microplate (Thermo Fisher Scientific) at 100 μL / well for immobilization (4° C. for 18 hours). After immobilization, the plate was blocked with 2% (w / v) skim milk (Becton Dickinson) and 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride.
[0114] (6-2) After washing the wells with a washing buffer (20 mM Tris-HCl buffer (pH 7.4) containing 0.05% (w / v) Tween 20 (Sigma-Aldrich) and 150 mM sodium chloride), the culture supernatant prepared in (3) was added, and the AAV-binding protein was reacted with VLP2 (at 30°C for 1 hour).
[0115] (6-3) After the reaction was completed, the plate was washed with the washing buffer, and 100 μL / well of Anti-6His antibody (manufactured by Bethyl Laboratories) diluted to 100 ng / mL was added.
[0116] (6-4) After incubation at 30°C for 1 hour and washing with the washing buffer, 50 μL / well of TMB Peroxidase Substrate (KPL) was added. 50 μL / well of 1 M phosphoric acid was added to stop color development, and the absorbance at 450 nm was measured using a microplate reader (Tecan).
[0117] The residual activity was calculated by dividing the binding activity between the AAV binding protein and VLP2 after alkali treatment by the binding activity between the AAV binding protein and VLP2 without alkali treatment.
[0118] (7) A random mutant library of approximately 1,800 strains was evaluated using the method described in (6), and transformants expressing AAV-binding proteins with improved residual activity compared to the parent molecule, AVR21, were selected from the library. The selected transformants were cultured, and an expression vector was prepared using a QIAprep Spin Miniprep kit (Qiagen).
[0119] (8) The nucleotide sequence of the polynucleotide region encoding the AAV-binding protein inserted into the resulting expression vector was analyzed using a fully automated DNA sequencer, Genetic Analyzer 3500 (manufactured by Thermo Fisher Scientific), to identify the amino acid substitution site. In this analysis, an oligonucleotide consisting of the sequence set forth in SEQ ID NO: 3 (5'-TAATACgACTCACTATAggg-3') or SEQ ID NO: 4 (5'-ATgCTAgTTATTgCTCAgCgg-3') was used as a sequencing primer.
[0120] Table 2 shows the amino acid substitution positions relative to AVR21 of the AAV binding proteins expressed by the transformants selected in (7) above, as well as the residual activity [%] after alkali treatment.
[0121] In the amino acid sequence of SEQ ID NO: 2, in the amino acid residues from serine (S) at position 25 to aspartic acid (D) at position 213, the following amino acids are listed: I319N (this notation indicates that isoleucine at position 319 in SEQ ID NO: 1 (position 32 in SEQ ID NO: 2) is substituted with asparagine, the same applies hereinafter), L321Q, L328P, N329K, N329S, V332A, E(V)335A (this notation indicates that glutamic acid at position 335 in SEQ ID NO: 1 (position 48 in SEQ ID NO: 2) is first substituted with valine in SEQ ID NO: 2 and then further substituted with alanine, the same applies hereinafter), K338R, E340G, T343A, T343S, Y344F, D345G, Q347K , T350A, E360D, Q365R, I366F, L367P, K368R, L369S, K(N)371D, K(N)371S, L376P, Y377F, Y377N, E378G, F(Y)379S, V(A)381T, I(V)382I, E384D, H389R, V394A, V394I, V396E, T397A AAV binding proteins having at least one of the following amino acid substitutions have been found to have improved alkaline stability compared to AVR21.
[0122]
[0123] Reference Example 1 Using the vector pET-AVR8g capable of expressing a polypeptide containing the AAV binding protein AVR8g (SEQ ID NO: 22) as a template, random mutations were introduced into the polynucleotide portion encoding the protein by error-prone PCR. In the polypeptide consisting of the amino acid sequence of SEQ ID NO: 22, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR8g, and the histidines (H) at positions 214 to 219 represent the tag sequence. AVR8g is a polypeptide in which the amino acid substitutions V317D, Y342C, K362E, K371N, G390S, K399E, S476R, and N487D have occurred in amino acid residues 312 to 500 of SEQ ID NO: 1, which corresponds to extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L (UniProt No. Q8IZA0) (WO2021 / 106882).
[0124] (1) Error-prone PCR was performed in the same manner as in Example 2(1), except that the plasmid pET-AVR8g, into which a polynucleotide (SEQ ID NO: 30) encoding AVR8g (SEQ ID NO: 29) had been inserted, was used as a template and the template concentration was 10 ng / μL. Mutations were introduced into the polynucleotide encoding AVR8g by the error-prone PCR, with the average mutation rate being 2.3 amino acid mutations per molecule.
[0125] (2) The PCR products obtained in (1) were purified, and then a random mutant library was prepared by the method described in Example 2 (2) and (3).
[0126] (3) The random mutant library (transformant) prepared in (2) was inoculated into 200 μL of 2YT liquid medium containing 50 μg / mL of kanamycin, and cultured overnight at 37°C with shaking using a 96-well deep-well plate.
[0127] (4) 10 μL of the culture solution prepared in (3) was subcultured into 500 μL of 2YT liquid medium containing 0.1 mM IPTG (IsoPropyl-β-D-ThioGalactopyranoside) and 50 μg / mL kanamycin, and further cultured overnight at 25°C with shaking using a 96-well deep-well plate.
[0128] (5) The culture supernatant obtained by centrifuging the culture medium (4) was diluted 16-fold with ultrapure water. 60 μL of the diluted culture supernatant was mixed with 60 μL of 0.1 M glycine sodium hydroxide buffer (pH 10.0) and subjected to heat and alkali treatment at 51.3° C. for 15 minutes.
[0129] (6) The binding activity of the AAV-binding protein to VLP2 when treated with (5) and when not treated with (5) was measured by the ELISA method described in Example 2(6).
[0130] The residual activity was calculated by dividing the binding activity between the AAV binding protein and VLP2 after heat treatment by the binding activity between the AAV binding protein and VLP2 after no heat treatment.
[0131] (7) A random mutant library of approximately 1,800 strains was evaluated using the method described in (6), and transformants expressing AAV-binding proteins with improved residual activity compared to the parent molecule, AVR8g, were selected from the library. The selected transformants were cultured, and an expression vector was prepared using a QIAprep Spin Miniprep kit (Qiagen).
[0132] (6) The sequence of the polynucleotide region encoding the AAV-binding protein inserted into the resulting expression vector was analyzed by the method described in Example 2(8) to identify the amino acid substitution sites.
[0133] (7) Table 3 shows the amino acid substitution positions relative to AVR8g and the residual activity [%] after heat and alkali treatment of the AAV binding proteins expressed by the transformants selected in (6).
[0134]
[0135] Reference Example 2 It was confirmed whether the thermal and alkaline stability would be improved by introducing any one of the amino acid substitutions (Y331H, F379S, K467N, and A491T) involved in improving the thermal and alkaline stability of AAV-binding proteins, as revealed in Reference Example 1, into AVR8g (SEQ ID NO: 22). Specifically, the thermal and alkaline stabilities of the following four types of AAV-binding proteins (a) to (d) were confirmed. (a) A protein in which the amino acid substitution Y331H has been introduced into AVR8g (SEQ ID NO: 24, designated AVR9a). (b) A protein in which the amino acid substitution F379S has been introduced into AVR8g (SEQ ID NO: 25, designated AVR9b). (c) A protein in which the amino acid substitution K467N has been introduced into AVR8g (SEQ ID NO: 26, designated AVR9c). (d) A protein in which the amino acid substitution A491T has been introduced into AVR8g (SEQ ID NO: 27, designated AVR9d). (1) A transformant capable of expressing any one of AVR9a (SEQ ID NO: 24), AVR9b (SEQ ID NO: 25), AVR9c (SEQ ID NO: 26), and AVR9d (SEQ ID NO: 27) (host: Escherichia coli BL21 strain (DE3)) was inoculated into 3 mL of 2xYT liquid medium containing 50 μg / mL of kanamycin, and pre-cultured overnight at 37°C under aerobic shaking.
[0136] (2) 2 mL of the preculture solution from (1) was inoculated into 200 mL of 2xYT liquid medium containing 50 μg / mL kanamycin in a 500 mL baffled flask, and the mixture was cultured aerobically at 37°C with shaking.
[0137] (3) After 2.0 hours from the start of the culture, the mixture was cooled on ice, IPTG was added to a final concentration of 0.1 mM, and the mixture was subsequently cultured aerobically with shaking at 25°C for 20 hours.
[0138] (4) After the cultivation was completed, the culture solution was centrifuged at 4°C and 8000 rpm for 20 minutes to collect each bacterial cell.
[0139] (5) The bacterial cells recovered in (4) were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole (hereinafter also referred to as "equilibration solution A") at a concentration of 5 mL / 1 g (bacterial cells), and then disrupted using an ultrasonic generator (Insonator 201M [Kubota Shoji Co., Ltd.]) at an output of approximately 150 W for approximately 10 minutes at 4°C. The disrupted bacterial cell solution was centrifuged twice at 8,000 rpm for 20 minutes at 4°C, and the supernatant was recovered from each suspension.
[0140] (6) The supernatant obtained in (5) was applied to an open column packed with 1.5 mL of Ni Sepharose 6 Fast Flow (manufactured by Cytiva) that had been previously equilibrated with equilibration solution A. After washing with equilibration solution A, the column was eluted with 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.
[0141] (7) Each eluate obtained in (6) was dialyzed against 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride to prepare an AAV-binding protein.
[0142] (8) The binding activity of the AAV-binding protein prepared in (7) to the VLP2 prepared in Example 1 was measured using the ELISA method described in (6) of Example 2. Based on the absorbance at 450 nm obtained as the measurement result, the AAV-binding protein obtained in (7) was diluted with pure water so that the measured values were similar.
[0143] (9) 60 μL of the diluted AAV binding protein solution was mixed with 60 μL of 0.1 M glycine sodium hydroxide buffer (pH 10.0), and subjected to heat and alkali treatment at 55.7° C., 60.1° C., 66.1° C., or 70° C. for 15 minutes.
[0144] (10) The binding activity of the AAV-binding protein to VLP2 when treated with (9) and when not treated with (9) was measured by the ELISA method described in (6) of Example 2. The binding activity of the AAV-binding protein to VLP2 when treated with (9) was divided by the binding activity of the AAV-binding protein to VLP2 when not treated with heat in (9) to calculate the residual activity.
[0145] The results are shown in Table 4. It can be said that an AAV binding protein having at least one amino acid substitution of Y331H, F379S, K467N, or A491T in the amino acid residues from serine (S) at position 25 to aspartic acid (D) at position 213 in the amino acid sequence of AVR8g (SEQ ID NO: 29) has improved heat and alkali stability compared to AVR8g.
[0146]
[0147] Example 3: Preparation of AVR21 amino acid substitution aggregate N329K, K338R, E401G, T426A, and A461P were selected from the amino acid substitutions involved in improving the alkaline stability of AAV-binding proteins revealed in Example 2, and K467N was selected from the amino acid substitutions involved in improving the heat and alkaline stability of AAV-binding proteins revealed in Reference Examples 1 and 2. These amino acid substitutions were then enriched in AVR21 (SEQ ID NO: 2) to further improve alkaline stability. Specifically, five types of AAV-binding proteins shown in (a) to (e) below were designed and prepared. (a) An AAV binding protein in which amino acid substitutions N329K, E401G, and T426A have been introduced into AVR21 (SEQ ID NO: 5, designated AVR24a). (b) An AAV binding protein in which amino acid substitutions K338R, T426A, and A461P have been introduced into AVR21 (SEQ ID NO: 6, designated AVR24b). (c) An AAV binding protein in which amino acid substitutions N329K, E401G, T426A, and A461P have been introduced into AVR21 (SEQ ID NO: 7, designated AVR25a). (d) An AAV binding protein in which amino acid substitutions K338R, E401G, T426A, and A461P have been introduced into AVR21 (SEQ ID NO: 8, designated AVR25b). (e) An AAV-binding protein in which the following amino acid substitutions have been introduced into AVR21: N329K, K338R, E401G, T426A, and A461P (SEQ ID NO: 9, designated AVR26). Hereinafter, methods for producing the six types of AAV-binding proteins shown in (a) to (e) above will be described.
[0148] A PCR primer set for generating a mutation cluster was designed. Specifically, the PCR primers for introducing the N329K amino acid substitution were SEQ ID NOs: 10 (forward) and 11 (reverse), the PCR primers for introducing the K338R amino acid substitution were SEQ ID NOs: 12 (forward) and 13 (reverse), the PCR primers for introducing the E401G amino acid substitution were SEQ ID NOs: 14 (forward) and 15 (reverse), the PCR primers for introducing the T426A amino acid substitution were SEQ ID NOs: 16 (forward) and 17 (reverse), and the PCR primers for introducing the A461P amino acid substitution were SEQ ID NOs: 18 (forward) and 19 (reverse).
[0149] (a) AVR24a This protein was prepared by selecting N329K, E401G, and T426A from the amino acid substitutions involved in alkaline stability identified in Example 2 and introducing these amino acid substitutions into AVR21 (SEQ ID NO: 2).
[0150] (a-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 10 (5'-AGCTGAAAGTCTACGTACTGCTGGT-3') and SEQ ID NO: 11 (5'-TAGACTTTCAGCTGGGCTTCATGTT-3') as PCR primers to prepare a reaction solution having the composition shown in Table 5. The reaction solution was then heat-treated at 98°C for 5 minutes, and 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0151]
[0152] (a-2) Using the PCR product obtained in (a-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 14 (5'-AGCCTGGCCCGCGCAAGAATCGTCC-3') and SEQ ID NO: 15 (5'-CGCGGGCCAGGCTCAACCGTTACGT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0153] (a-3) Using the PCR product obtained in (a-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 16 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 17 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0154] (a-4) The PCR product obtained in (a-3) was used to transform Escherichia coli strain BL21 (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then collected by centrifugation. A plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR24a containing a polynucleotide encoding AVR24a, which had 24 amino acid substitutions relative to the native AAV binding protein.
[0155] (a-5) The nucleotide sequence of pET-AVR24a was analyzed and confirmed in the same manner as in Example 2(8).
[0156] The amino acid sequence of AVR24a with a signal sequence and a polyhistidine tag added is shown in SEQ ID NO: 5. In SEQ ID NO: 5, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR24a (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 5, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the tyrosine of K380R is at the 93rd position. Arginine is at position 93, alanine at position 94 of V381A, valine at position 95 of I382V, serine at position 103 of G390S, glutamic acid at position 112 of K399E, glycine at position 114 of E401G, alanine at position 139 of T426A, glutamine at position 180 of K467Q, arginine at position 189 of S476R, threonine at position 195 of S482T, aspartic acid at position 200 of N487D, and aspartic acid at position 205 of N492D.
[0157] (b) AVR24b This protein was prepared by selecting K338R, T426A, and A461P from the amino acid substitutions involved in alkaline stability identified in Example 2 and introducing these amino acid substitutions into AVR21 (SEQ ID NO: 2).
[0158] (b-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 12 (5'-CACCGCGCGGGGAAGCGTCAACGTA-3') and SEQ ID NO: 13 (5'-TCCCCGCGCGGTGGAACCAGCAGTA-3') as PCR primers to prepare a reaction solution having the composition shown in Table 5. The reaction solution was then heat-treated at 98°C for 5 minutes, and 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0159] (b-2) Using the PCR product obtained in (b-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 16 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 17 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally heat-treating at 72°C for 5 minutes.
[0160] (b-3) Using the PCR product obtained in (b-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 18 (5'-ATACCCCGATTCTTAAGCTCTCGCA-3') and SEQ ID NO: 19 (5'-AGAATCGGGGTATCCTCGCTGATCT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0161] (b-4) The PCR product obtained in (b-3) was used to transform Escherichia coli strain BL21 (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then collected by centrifugation. A plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR24b containing a polynucleotide encoding AVR24b, which had 24 amino acid substitutions relative to the native AAV binding protein.
[0162] (b-5) The nucleotide sequence of pET-AVR24b was analyzed and confirmed in the same manner as in Example 2(8).
[0163] The amino acid sequence of AVR24b with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 6. In SEQ ID NO: 6, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR24b (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 6, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the arginine of K338R is at the 51st position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the tyrosine of K380R is at the 93rd position. The arginine of V381A is at position 93, the alanine of V381A is at position 94, the valine of I382V is at position 95, the serine of G390S is at position 103, the glutamic acid of K399E is at position 112, the alanine of T426A is at position 139, the proline of A461P is at position 174, the glutamine of K467Q is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0164] (c) AVR25a This protein was prepared by selecting N329K, E401G, T426A, and A461P from the amino acid substitutions involved in alkaline stability identified in Example 2 and introducing these amino acid substitutions into AVR21 (SEQ ID NO: 2).
[0165] (c-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 10 (5'-AGCTGAAAGTCTACGTACTGCTGGT-3') and SEQ ID NO: 11 (5'-TAGACTTTCAGCTGGGCTTCATGTT-3') as PCR primers to prepare a reaction solution having the composition shown in Table 5. The reaction solution was then heat-treated at 98°C for 5 minutes, and 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0166] (c-2) Using the PCR product obtained in (c-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 14 (5'-AGCCTGGCCCGCGCAAGAATCGTCC-3') and SEQ ID NO: 15 (5'-CGCGGGCCAGGCTCAACCGTTACGT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0167] (c-3) Using the PCR product obtained in (c-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 16 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 17 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0168] (c-4) Using the PCR product obtained in (c-3) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 18 (5'-ATACCCCGATTCTTAAGCTCTCGCA-3') and SEQ ID NO: 19 (5'-AGAATCGGGGTATCCTCGCTGATCT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0169] (c-5) The PCR product obtained in (c-4) was used to transform Escherichia coli strain BL21 (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then collected by centrifugation. A plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR25a containing a polynucleotide encoding AVR25a, which had 25 amino acid substitutions relative to the native AAV binding protein.
[0170] (c-6) The nucleotide sequence of pET-AVR25a was analyzed and confirmed in the same manner as in Example 2(8).
[0171] The amino acid sequence of AVR25a with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 7. In SEQ ID NO: 7, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR25a (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 7, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, and the arginine of K380R is at position 93. In the first half, the alanine of V381A is at position 94, the valine of I382V is at position 95, the serine of G390S is at position 103, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the proline of A461P is at position 174, the glutamine of K467Q is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0172] (d) AVR25b This protein was prepared by selecting K338R, E401G, T426A, and A461P from the amino acid substitutions involved in alkaline stability identified in Example 2 and introducing these amino acid substitutions into AVR21 (SEQ ID NO: 2).
[0173] (d-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 12 (5'-CACCGCGCGGGGAAGCGTCAACGTA-3') and SEQ ID NO: 13 (5'-TCCCCGCGCGGTGGAACCAGCAGTA-3') as PCR primers to prepare a reaction solution having the composition shown in Table 5, followed by heat-treating the reaction solution at 98°C for 5 minutes, and carrying out 30 cycles of reaction consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0174] (d-2) Using the PCR product obtained in (d-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 14 (5'-AGCCTGGCCCGCGCAAGAATCGTCC-3') and SEQ ID NO: 15 (5'-CGCGGGCCAGGCTCAACCGTTACGT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0175] (d-3) Using the PCR product obtained in (d-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 16 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 17 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0176] (d-4) Using the PCR product obtained in (d-3) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 18 (5'-ATACCCCGATTCTTAAGCTCTCGCA-3') and SEQ ID NO: 19 (5'-AGAATCGGGGTATCCTCGCTGATCT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally heat-treating at 72°C for 5 minutes.
[0177] (d-5) The PCR product obtained in (d-4) was used to transform Escherichia coli strain BL21 (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then collected by centrifugation. A plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR25b containing a polynucleotide encoding AVR25b, which had 25 amino acid substitutions relative to the native AAV binding protein.
[0178] (d-6) The nucleotide sequence of pET-AVR25b was analyzed and confirmed in the same manner as in Example 2(8).
[0179] The amino acid sequence of AVR25b with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 8. In SEQ ID NO: 8, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR25b (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 8, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the arginine of K338R is at the 51st position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the arginine of K380R is at the 93rd position. th, the alanine of V381A is at position 94, the valine of I382V is at position 95, the serine of G390S is at position 103, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the proline of A461P is at position 174, the glutamine of K467Q is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0180] (e) AVR26 This protein was prepared by selecting N329K, K338R, E401G, T426A, and A461P from the amino acid substitutions involved in alkaline stability identified in Example 2 and introducing these amino acid substitutions into AVR21 (SEQ ID NO: 2).
[0181] (e-1) PCR was performed by using vector pET-AVR21 capable of expressing a polypeptide containing AVR21 (SEQ ID NO: 2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 10 (5'-AGCTGAAAGTCTACGTACTGCTGGT-3') and SEQ ID NO: 11 (5'-TAGACTTTCAGCTGGGCTTCATGTT-3') as PCR primers to prepare a reaction solution having the composition shown in Table 5, followed by heat-treating the reaction solution at 98°C for 5 minutes, and carrying out 30 cycles of reaction consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0182] (e-2) Using the PCR product obtained in (e-1) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 12 (5'-CACCGCGCGGGGAAGCGTCAACGTA-3') and SEQ ID NO: 13 (5'-TCCCCGCGCGGTGGAACCAGCAGTA-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally heat-treating at 72°C for 5 minutes.
[0183] (e-3) Using the PCR product obtained in (e-2) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 14 (5'-AGCCTGGCCCGCGCAAGAATCGTCC-3') and SEQ ID NO: 15 (5'-CGCGGGCCAGGCTCAACCGTTACGT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally heat-treating at 72°C for 5 minutes.
[0184] (e-4) Using the PCR product obtained in (e-3) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 16 (5'-CAAGTGCGGTGATCGACGGATCGCA-3') and SEQ ID NO: 17 (5'-ATCACCGCACTTGTAGTCGGGAGTG-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally heat-treating at 72°C for 5 minutes.
[0185] (e-5) Using the PCR product obtained in (e-4) as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 18 (5'-ATACCCCGATTCTTAAGCTCTCGCA-3') and SEQ ID NO: 19 (5'-AGAATCGGGGTATCCTCGCTGATCT-3') as PCR primers, a reaction solution having the composition shown in Table 5 was prepared, and the reaction solution was then heat-treated at 98°C for 5 minutes. PCR was then performed by performing 30 cycles of reaction, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, and finally heat-treating at 72°C for 5 minutes.
[0186] (e-6) The PCR product obtained in (e-5) was used to transform Escherichia coli strain BL21 (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the resulting transformant was then collected by centrifugation. A plasmid was extracted from the transformant to obtain a plasmid (expression vector) pET-AVR26 containing a polynucleotide encoding AVR26, which had 26 amino acid substitutions relative to the native AAV binding protein.
[0187] (e-7) The nucleotide sequence of pET-AVR26 was analyzed and confirmed in the same manner as in Example 2(8).
[0188] The amino acid sequence of AVR26 with a signal sequence and a polyhistidine tag added is shown in SEQ ID NO: 9. In SEQ ID NO: 9, the portion from methionine (M) at position 1 to alanine (A) at position 22 is the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 is the AAV binding protein AVR26 (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 is the tag sequence. In SEQ ID NO: 9, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the arginine of K338R is at the 51st position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the arginine of K380R is at the 51st position. Arginine is at position 93, alanine at position 94 of V381A, valine at position 95 of I382V, serine at position 103 of G390S, glutamic acid at position 112 of K399E, glycine at position 114 of E401G, alanine at position 139 of T426A, proline at position 174 of A461P, glutamine at position 180 of K467Q, arginine at position 189 of S476R, threonine at position 195 of S482T, aspartic acid at position 200 of N487D, and aspartic acid at position 205 of N492D.
[0189] Example 4 Evaluation of Alkaline Stability of AVR21 Amino Acid Substitution Assembly (1) As transformants capable of expressing AAV-binding proteins, the Escherichia coli strain BL21(DE3) was transformed with a plasmid containing a polynucleotide encoding any of the six types of AAV-binding proteins (AVR21 amino acid substitution assembly obtained in Example 3, specifically, AVR24a [SEQ ID NO: 5], AVR24b [SEQ ID NO: 6], AVR25a [SEQ ID NO: 7], AVR25b [SEQ ID NO: 8], and AVR26 [SEQ ID NO: 9], and AVR21 (SEQ ID NO: 2)). The resulting transformants were each inoculated into 3 mL of 2xYT liquid medium containing 50 μg / mL kanamycin and pre-cultured overnight at 37°C under aerobic shaking.
[0190] (2) 2 mL of the preculture solution from (1) was inoculated into 200 mL of 2xYT liquid medium containing 50 μg / mL kanamycin in a 1 L baffled flask, and the mixture was cultured aerobically at 37°C with shaking.
[0191] (3) After 2.0 hours from the start of the culture, the mixture was cooled on ice, IPTG was added to a final concentration of 0.1 mM, and the mixture was subsequently cultured aerobically with shaking at 25°C for 20 hours.
[0192] (4) After the cultivation was completed, the culture solution was centrifuged at 4°C and 8000 rpm for 20 minutes to recover each cultured bacterial body (transformant).
[0193] (5) The bacterial cells recovered in (4) were suspended in 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride and 20 mM imidazole (hereinafter also referred to as "equilibration solution A") at a concentration of 5 mL / 1 g (bacterial cells), and then disrupted using an ultrasonic generator (Insonator 201M (Kubota Shoji Co., Ltd.)) at 8°C for approximately 10 minutes at an output of approximately 150 W. The disrupted bacterial cell solution was centrifuged twice at 8,000 rpm for 20 minutes at 4°C, and the supernatant was recovered from each suspension.
[0194] (6) The supernatant obtained in (5) was applied to an open column packed with 1.5 mL of Ni Sepharose 6 Fast Flow (manufactured by Cytiva) that had been previously equilibrated with equilibration solution A. After washing with equilibration solution A, the column was eluted with 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole and 150 mM sodium chloride.
[0195] (7) Each eluate obtained in (6) was dialyzed against 20 mM Tris-HCl buffer (pH 7.4) containing 150 mM sodium chloride to prepare an AAV-binding protein.
[0196] (8) Using the ELISA method described in Example 2(6), the binding activity of the AAV-binding protein prepared in (7) to the VLP2 prepared in Example 1 was measured. Based on the absorbance at 450 nm obtained as the measurement result, the AAV-binding protein obtained in (7) was diluted with pure water so that the measured values were similar.
[0197] (9) Each AAV-binding protein solution diluted in (8) was divided into two fractions. One fraction was mixed with an equal volume of 0.5 M aqueous sodium hydroxide and subjected to alkali treatment by standing at a fixed temperature for a fixed period of time (treatment temperature: 30°C, treatment time: 0, 30, 60 minutes), while the other fraction was not subjected to the alkali treatment (corresponding to the "start" of alkali treatment).
[0198] (10) The fraction after treatment in (9) was mixed with 0.5 M MES (2-(N-morpholino) ethanol sulfonic acid) buffer (pH 6.0) in a ratio of 8:2 to adjust the pH to around 6, and then the binding activity to VLP2 was measured by the ELISA method described in Example 2(6).
[0199] (11) The residual activity was calculated by dividing the absorbance at 450 nm after the alkali treatment in (10) by the absorbance at 450 nm after the treatment time of 0 hours.
[0200] The results are shown in Table 6. It can be seen that all of the AVR21 amino acid substitution aggregates obtained in Example 3 had higher residual activity and improved alkali stability compared to AVR21 (SEQ ID NO: 2).
[0201]
[0202] Example 5: Preparation of AAV Vector (Part 2) The AAV vector used as the AAV in the following examples was prepared by the following method.
[0203] (1) A nucleotide sequence (SEQ ID NO: 21) was designed in which a restriction enzyme EcoRI recognition sequence (GAATTC) was added to the 5'-end of a polynucleotide encoding EGFP (Enhanced Green Fluorescent Protein) consisting of the amino acid sequence set forth in SEQ ID NO: 20, and a stop codon (TAG) and a BamHI recognition sequence (GGATTC) were added to the 3'-end.
[0204] (2) A polynucleotide consisting of the sequence set forth in SEQ ID NO:21 was totally synthesized and cloned into a plasmid (outsourced to FASMAC, designated pUC-EGFP). Escherichia coli JM109 strain was transformed with pUC-EGFP, and the resulting transformant was cultured. pUC-EGFP was extracted from the culture medium using a QIAprep Spin Miniprep kit (Qiagen).
[0205] (3) The pUC-EGFP obtained in (2) was digested with the restriction enzymes EcoRI and BamHI, and then ligated into the expression vector pAAV-CMV (manufactured by Takara Bio Inc.) which had been previously digested with the restriction enzymes EcoRI and BamHI. The ligation product was used to transform the Escherichia coli JM109 strain.
[0206] (4) The transformant obtained in (3) was cultured overnight at 37°C with shaking in a 5-L baffled flask containing 1 L of 2YT medium (1.6% (w / v) tryptone, 1% (w / v) yeast extract, 0.5% (w / v) sodium chloride) containing 100 μg / mL carbenicillin. After the culture was completed, the cells were collected by centrifugation, and pAAV-EGFP was prepared in large quantities from the collected cells using a Plasmid Mega Kit (Qiagen).
[0207] (5) Escherichia coli JM109 strain was transformed with a plasmid containing a polynucleotide encoding the capsid of serotype 8 (AAV8) (hereinafter also referred to as "pRC8 Vector") and pHelper Vector (manufactured by Takara Bio Inc.). The obtained transformant was used in the same procedure as in (4) to prepare large quantities of pRCX Vector and pHelper.
[0208] (6) HEK293T cells were cultured in ten T-225 flasks (Thermo Fisher Scientific) containing 45 mL of D-MEM medium (Fujifilm Wako Pure Chemical Industries, Ltd.) containing 10% (v / v) bovine serum. Gene transfer was performed by adding the pAAV-EGFP prepared in (4), the pRC8 Vector prepared in (5), pHelper, and a complex of polyethyleneimine (Polysciences), and the cells were then statically cultured for 3 days under conditions of 5% (v / v) carbon dioxide and 37°C. After culture, the cells were detached by centrifugation and collected. Each cell obtained from five T-225 flasks was frozen and stored at -80°C.
[0209] (7) The frozen cells obtained in (6) were thawed and suspended in 10 mL of 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M sodium chloride, 4 mM magnesium chloride, and 0.01% (w / v) Tween 20 (Sigma-Aldrich). A 1 / 2000 volume of Benzonase (Merck Millipore) was added, and the mixture was left to stand at 37°C for 1 hour. The mixture was then centrifuged at 13,000 x g and 4°C for 10 minutes to obtain a supernatant. Ammonium sulfate was added to the resulting supernatant to a 15% saturation level, and the mixture was centrifuged again under the same conditions. The resulting supernatant was passed through a 0.45 μm pore size filter to remove any floating material.
[0210] (8) The supernatant from which the suspended matter had been removed was applied to a 7 mL POROS AAVX column (manufactured by Thermo Fisher Scientific) that had been equilibrated in advance with 20 mM Tris-HCl buffer (pH 8.0) containing 0.5 M sodium chloride (hereinafter also referred to as "equilibration solution B").
[0211] (9) After washing with equilibration solution B, elution was performed with 0.1 M acetate buffer (pH 2.5) containing 0.5 M sodium chloride. The resulting eluate was neutralized by adding 1 / 4 volume of 1 M Tris-HCl buffer (pH 8.5) containing 20 mM magnesium chloride to obtain a solution of the AAV vector AAV8-EGFP.
[0212] (10) The AAV8-EGFP concentration in the solution obtained in (9) was quantified by qPCR using an AAVpro Titration Kit (manufactured by Takara Bio Inc.). The solution was subjected to SDS-PAGE and silver stained using a Pierce Silver Stain Kit (manufactured by Thermo Fisher Scientific) to confirm the purity of the AAV vector contained in the solution.
[0213] Example 6 Introduction of Amino Acid Substitution into AAV-Binding Protein AVR25a AVR25a (SEQ ID NO: 7) was selected from the AVR21 amino acid substitution aggregates evaluated for alkaline stability in Example 4, and an AVR21 amino acid substitution aggregate (designated AVR25c) was prepared by introducing the amino acid substitution K467N into AVR25a, which was found to be an amino acid substitution that improves thermal and alkaline stability in Reference Examples 1 and 2. SEQ ID NOs: 29 (forward) and 30 (reverse), respectively, were designed as PCR primers for introducing the K467N amino acid substitution.
[0214] (1) PCR was performed in the same manner as in Example 3(a-1), except that the vector pET-AVR25a capable of expressing a polypeptide containing AVR25a (SEQ ID NO: 7) was used as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 29 (5'-GAGAGCTTAAGAATGGGGGTATCCTC-3') and SEQ ID NO: 30 (5'-TTCTTAAGCTCTCGAATCTGGTACC-3') were used as PCR primers.
[0215] (2) From the PCR product obtained in (1), a plasmid (expression vector) pET-AVR25c containing a polynucleotide encoding AVR25c, which had 25 amino acid substitutions relative to the native AAV binding protein, was obtained in the same manner as in Example 3(a-4).
[0216] (3) The nucleotide sequence of pET-AVR25c was analyzed and confirmed in the same manner as in Example 2(8).
[0217] The amino acid sequence of AVR25c with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 28. In SEQ ID NO: 28, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR25c (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 28, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, and the arginine of K380R is at position 93. In the first half, the alanine of V381A is at position 94, the valine of I382V is at position 95, the serine of G390S is at position 103, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0218] Example 7 Evaluation of alkaline stability of AAV-binding protein AVR25c E. coli strain BL21(DE3) was transformed with the plasmid containing the polynucleotide encoding AVR25c (SEQ ID NO:28) obtained in Example 6, or the plasmid encoding the AAV-binding protein AVR25a (SEQ ID NO:7) obtained in Example 3(c), and the resulting transformants were cultured in the same manner as in Examples 4(1) to (3). The cultured cells were then recovered by the method described in Example 4(4). An AAV-binding protein was prepared by the method described in Examples 4(5) to (8), and its alkaline stability was evaluated by the methods described in Examples 4(9) to (11).
[0219] The results are shown in Table 7. It can be seen that AVR25c (SEQ ID NO: 28) into which the amino acid substitution K467N has been introduced has higher residual activity and improved alkali stability compared to AVR25a (SEQ ID NO: 7) without the amino acid substitution.
[0220]
[0221] Example 8: Preparation and Screening of AAV-binding Protein Mutation Library (Part 3) Using the vector pET-AVR25c capable of expressing the polypeptide (SEQ ID NO: 28) containing the AAV-binding protein AVR25c prepared in Example 6 as a template, random mutations were introduced into the polynucleotide portion encoding the protein using error-prone PCR.
[0222] (1) Error-prone PCR was performed in the same manner as described in Example 2(1), except that the vector pET-AVR25c capable of expressing a polypeptide containing AVR25c (SEQ ID NO: 28) was used as a template. Mutations were successfully introduced into the polynucleotide encoding the AAV binding protein by the error-prone PCR, with the average mutation introduction rate being 1.8 amino acid mutations per molecule.
[0223] (2) A random mutant library was prepared from the PCR products obtained in (1) by the methods described in Example 2 (2) and (3).
[0224] (3) The random mutant library (transformant) prepared in (2) was inoculated into 200 μL of 2xYT liquid medium containing 50 μg / mL of kanamycin, and cultured overnight at 37°C with shaking using a 96-well deep-well plate.
[0225] (4) The culture medium (3) was centrifuged, and the resulting culture supernatant was diluted 2-fold with ultrapure water. 50 μL of the diluted culture supernatant was mixed with 50 μL of 1 M aqueous sodium hydroxide solution, and then subjected to alkali treatment at 30° C. for 15 minutes.
[0226] (5) The binding activity of the AAV-binding protein to VLP2 after treatment in (4) and without treatment in (4) was evaluated by the ELISA method described in (6) of Example 2. The binding activity of the AAV-binding protein to VLP2 after alkali treatment was divided by the binding activity of the AAV-binding protein to VLP2 without alkali treatment to calculate the residual activity.
[0227] (6) A random mutant library of approximately 1,800 strains was evaluated using the method described in (5), and transformants expressing AAV-binding proteins with improved residual activity compared to the parent molecule, AVR25c, were selected from the library.
[0228] (7) The transformant selected in (6) was cultured, and an expression vector was prepared using a QIAprep Spin Miniprep kit (Qiagen). The sequence of the polynucleotide region encoding the AAV-binding protein inserted into the vector was analyzed by the method described in Example 2(8) (subcontracted to FASMAC), and the amino acid substitution site was identified.
[0229] Table 8 shows the amino acid substitution positions relative to AVR25c of the AAV binding proteins expressed by the transformants selected in (7) above, as well as the residual activity [%] after alkali treatment.
[0230] In the amino acid sequence of SEQ ID NO: 2, the amino acid residues from the 25th serine (S) to the 500th aspartic acid (D) are: G314D, V(D)317G, Q318R, P322A, E325V, Q347R, T350A, E362D, H363P, I366F, E378G, F(Y)379N, G392E, V394A, V398A, E399K, R406H, Q415R, F4 An AAV binding protein having at least one amino acid substitution selected from the group consisting of 16L, L421P, S433G, T434S, D437V, E445K, K455R, S457R, T474R, T478I, A485V, T486A, L493M, N496D, K497E, V499I, and D500G can be said to have improved alkaline stability compared to AVR25c (SEQ ID NO: 28).
[0231]
[0232] Example 9 Preparation of AVR25c Amino Acid Substitution Assembly (Part 1) From the amino acid substitutions involved in improving the alkaline stability of AAV-binding proteins revealed in Example 8, G314D, I366F, V394A, K455R, T474R, K467E, and V499I were selected, and these amino acid substitutions were accumulated in AVR25c (SEQ ID NO: 28) to further improve alkaline stability. Specifically, the following nine types of AAV-binding proteins (a) to (i) were designed and prepared. (a) An AAV binding protein in which the amino acid substitutions I366F and T474R have been introduced into AVR25c (SEQ ID NO: 31, designated AVR27b). (b) An AAV binding protein in which the amino acid substitutions V394A and T474R have been introduced into AVR25c (SEQ ID NO: 32, designated AVR27c). (c) An AAV binding protein in which the amino acid substitutions K455R and T474R have been introduced into AVR25c (SEQ ID NO: 33, designated AVR27d). (d) An AAV binding protein in which the amino acid substitutions I366F, V394A, and K455R have been introduced into AVR25c (SEQ ID NO: 34, designated AVR28). (e) An AAV binding protein in which the amino acid substitutions I366F, V394A, K455R, and T474R have been introduced into AVR25c (SEQ ID NO: 35, designated AVR29a). (f) An AAV binding protein in which the amino acid substitutions G314D, I366F, V394A, and K455R have been introduced into AVR25c (SEQ ID NO: 36, designated AVR29b). (g) An AAV binding protein in which the amino acid substitutions I366F, V394A, K455R, and K497E have been introduced into AVR25c (SEQ ID NO: 37, designated AVR29c). (h) An AAV binding protein in which the amino acid substitutions I366F, V394A, K455R, and V499I have been introduced into AVR25c (SEQ ID NO: 38, designated AVR29d). (i) An AAV-binding protein in which the following amino acid substitutions have been introduced into AVR25c: G314D, I366F, V394A, K455R, K497E, and V499I (SEQ ID NO: 39, designated AVR31). Hereinafter, methods for producing the nine types of AAV-binding proteins shown in (a) to (i) above will be described.
[0233] A PCR primer set for generating a mutation cluster was designed. Specifically, SEQ ID NOs: 40 (forward) and 41 (reverse) were used as PCR primers for introducing the G314D amino acid substitution, SEQ ID NOs: 42 (forward) and 43 (reverse) were used as PCR primers for introducing the I366F amino acid substitution, SEQ ID NOs: 44 (forward) and 45 (reverse) were used as PCR primers for introducing the V394A amino acid substitution, SEQ ID NOs: 46 (forward) and 47 (reverse) were used as PCR primers for introducing the K455R amino acid substitution, SEQ ID NOs: 48 (forward) and 49 (reverse) were used as PCR primers for introducing the T474R amino acid substitution, and SEQ ID NOs: 50 (forward) and 51 (reverse) were used as PCR primers for introducing the K497E amino acid substitution. SEQ ID NOs: 52 (forward) and 53 (reverse) were designed as PCR primers for introducing the V499I amino acid substitution, and SEQ ID NOs: 54 (forward) and 55 (reverse) were designed as PCR primers for introducing the K497E and V499I amino acid substitutions.
[0234] (a) AVR27b This protein was prepared by selecting I366F and T474R from the amino acid substitutions involved in alkaline stability identified in Example 9, and introducing I366F, one of the amino acid substitutions, into the AAV-binding protein obtained in Example 8, in which the amino acid substitution T474R had been introduced into AVR25c (see Table 8; hereinafter also referred to as "AVR25c_T474R").
[0235] (a-1) PCR was performed by using a vector capable of expressing AVR25c_T474R as a template and oligonucleotides consisting of the sequences of SEQ ID NO: 42 (5'-GTCAGTTTCTGAAATTATCCAACTT-3') and SEQ ID NO: 43 (5'-TTCAGAAAACTGACTGTGTTCGCCTT-3') as PCR primers to prepare a reaction solution having the composition shown in Table 9. The reaction solution was then heat-treated at 98°C for 5 minutes, and 30 cycles of reaction were carried out, each cycle consisting of a first step at 98°C for 10 seconds, a second step at 55°C for 5 seconds, and a third step at 72°C for 6 minutes, followed by a final heat treatment at 72°C for 5 minutes.
[0236]
[0237] (a-2) The PCR product obtained in (a-1) was treated with DpnI (New England Biolabs) to digest the template strand, and the PCR product was then used to transform Escherichia coli strain BL21 (DE3). The resulting transformant was cultured in LB medium supplemented with 50 μg / mL kanamycin, and the bacterial cells (transformant) were collected by centrifugation. A plasmid was extracted from the cultured cells to obtain a plasmid (expression vector) pET-AVR27b containing a polynucleotide encoding AVR27b, which has 27 amino acid substitutions relative to the native AAV binding protein.
[0238] (a-3) The nucleotide sequence of pET-AVR27b was analyzed and confirmed in the same manner as in Example 2(8).
[0239] The amino acid sequence of AVR27b with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 31. In SEQ ID NO: 31, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR27b (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 31, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the phenylalanine of I366F is at the 79th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the arginine of K380R is at the 93rd position. th, the alanine of V381A is at position 94, the valine of I382V is at position 95, the serine of G390S is at position 103, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of T474R is at position 187, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0240] (b) AVR27c This protein was prepared by selecting V394A and T474R from the amino acid substitutions involved in alkaline stability identified in Example 8, and introducing V394A into AVR25c_T474R.
[0241] (b-1) PCR was performed in the same manner as in (a-1), except that a vector capable of expressing AVR25c_T474R was used as a template and oligonucleotides consisting of the sequences of SEQ ID NO: 44 (5'-GGTATGCGAACGTAACGGTTGAGCC-3') and SEQ ID NO: 45 (5'-ACGTTCGCATACCCCTCGGAATGCG-3') were used as PCR primers.
[0242] (b-2) From the PCR product obtained in (b-1), a plasmid (expression vector) pET-AVR27c containing a polynucleotide encoding AVR27c in which 27 amino acids were substituted relative to the native AAV binding protein was obtained in the same manner as in (a-2).
[0243] (b-3) The nucleotide sequence of pET-AVR27c was analyzed and confirmed in the same manner as in Example 2(8).
[0244] The amino acid sequence of AVR27c with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 32. In SEQ ID NO: 32, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR27c (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 32, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, the arginine of K380R is at position 93, and the alanine of V381A is at position 94. In the nucleotide sequence, the valine of I382V is at position 95, the serine of G390S is at position 103, the alanine of V394A is at position 107, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of T474R is at position 187, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0245] (c) AVR27d This protein was produced by selecting K455R and T474R from the amino acid substitutions involved in alkaline stability that were revealed in Example 8, and introducing K455R, among the amino acid substitutions, into a vector capable of expressing AVR25c_T474R as a template.
[0246] (c-1) PCR was performed in the same manner as in (a-1), except that a vector capable of expressing AVR25c_T474R was used as a template and oligonucleotides consisting of the sequences of SEQ ID NO: 46 (5'-AAGAACGCATCAGCGAGGATACCCC-3') and SEQ ID NO: 47 (5'-CTGATGCGTTCTTCACGGAGCGGGC-3') were used as PCR primers.
[0247] (c-2) From the PCR product obtained in (c-1), a plasmid (expression vector) pET-AVR27d containing a polynucleotide encoding AVR27d, in which 27 amino acids were substituted relative to the native AAV binding protein, was obtained in the same manner as in (a-2).
[0248] (c-3) The nucleotide sequence of pET-AVR27d was analyzed and confirmed in the same manner as in Example 2(8).
[0249] The amino acid sequence of AVR27d with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 33. In SEQ ID NO: 33, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR27d (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 33, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, the arginine of K380R is at the 93rd position, and the alanine of V381A is at the 94th position. , I382V valine is at position 95, G390S serine is at position 103, K399E glutamic acid is at position 112, E401G glycine is at position 114, T426A alanine is at position 139, K455R arginine is at position 168, A461P proline is at position 174, K467N asparagine is at position 180, T474R arginine is at position 187, S476R arginine is at position 189, S482T threonine is at position 195, N487D aspartic acid is at position 200, and N492D aspartic acid is at position 205.
[0250] (d) AVR28 For this protein, I366F, V394A, and K455R were selected from the amino acid substitutions involved in alkaline stability that were revealed in Example 8. Since this protein was already obtained in Example 8 (see Table 8), it was used.
[0251] The amino acid sequence of AVR28 with a signal sequence and a polyhistidine tag added is shown in SEQ ID NO: 34. In SEQ ID NO: 34, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR28a (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 34, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the phenylalanine of I366F is at the 79th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, the arginine of K380R is at the 93rd position, and the arginine of V381A is at the 94th position. alanine at position 94, valine at position 95, serine at position G390S, alanine at position V394A, glutamic acid at position K399E, glycine at position E401G, alanine at position 107, glutamic acid at position K399E, glycine at position E401G, alanine at position T426A, arginine at position K455R, proline at position A461P, asparagine at position K467N, arginine at position S476R, threonine at position S482T, aspartic acid at position N487D, and aspartic acid at position N492D.
[0252] (e) AVR29a This protein was prepared by selecting T474R from the amino acid substitutions involved in alkaline stability identified in Example 8 and introducing this amino acid substitution into AVR28 (SEQ ID NO: 34).
[0253] (e-1) PCR was performed in the same manner as in (a-1), except that vector pET-AVR28a capable of expressing a polypeptide containing AVR28 (SEQ ID NO: 34) was used as a template and oligonucleotides consisting of the sequences of SEQ ID NO: 48 (5'-ACTACCGCTTTCGCCTGACCGTGAC-3') and SEQ ID NO: 49 (5'-CGAAAGCGGTAGTTACCTGGTACCA-3') were used as PCR primers.
[0254] (e-2) From the PCR product obtained in (e-1), a plasmid (expression vector) pET-AVR29a containing a polynucleotide encoding AVR29a, which had 29 amino acid substitutions relative to the native AAV binding protein, was obtained in the same manner as in (a-2).
[0255] (e-3) The nucleotide sequence of pET-AVR29a was analyzed and confirmed in the same manner as in Example 2(8).
[0256] The amino acid sequence of AVR29a with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 35. In SEQ ID NO: 35, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR29a (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 35, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the phenylalanine of I366F is at position 79, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, the arginine of K380R is at position 93, and the alanine of V381A is at position 94. In the first half, the valine of I382V is at position 95, the serine of G390S is at position 103, the alanine of V394A is at position 107, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the arginine of K455R is at position 168, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of T474R is at position 187, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0257] (f) AVR29b This protein was prepared by selecting G314D from the amino acid substitutions involved in alkaline stability identified in Example 9 and introducing this amino acid substitution into AVR28 (SEQ ID NO: 34).
[0258] (f-1) PCR was carried out in the same manner as in (e-1), except that oligonucleotides consisting of the sequences set forth in SEQ ID NO: 40 (5'-CTGCAGATGAAAGCGACCAAATCAC-3') and SEQ ID NO: 41 (5'-CTTTCATCTGCAGAGCCCATGGCCA-3') were used as PCR primers.
[0259] (f-2) From the PCR product obtained in (f-1), a plasmid (expression vector) pET-AVR29b containing a polynucleotide encoding AVR29b, which has 29 amino acid substitutions relative to the native AAV binding protein, was obtained in the same manner as in (a-2).
[0260] (f-3) The nucleotide sequence of pET-AVR29b was analyzed and confirmed in the same manner as in Example 2(8).
[0261] The amino acid sequence of AVR29b with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 36. In SEQ ID NO: 36, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR29b (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 36, the aspartic acid of G314D is at the 27th position, the aspartic acid of V317D is at the 30th position, the histidine of N324H is at the 37th position, the alanine of V326A is at the 39th position, the lysine of N329K is at the 42nd position, the valine of A330V is at the 43rd position, the leucine of Q334L is at the 47th position, the valine of E335V is at the 48th position, the alanine of T341A is at the 54th position, the serine of Y342S is at the 55th position, the glutamic acid of K362E is at the 75th position, the phenylalanine of I366F is at the 79th position, the asparagine of K371N is at the 84th position, the tyrosine of F379Y is at the 92nd position, and the arginine of K380R is at the 93rd position. Third, the alanine of V381A is at position 94, the valine of I382V is at position 95, the serine of G390S is at position 103, the alanine of V394A is at position 107, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the arginine of K455R is at position 168, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, and the aspartic acid of N492D is at position 205.
[0262] (g) AVR29c This protein was prepared by selecting K497E from the amino acid substitutions involved in alkaline stability identified in Example 8 and introducing this amino acid substitution into AVR28 (SEQ ID NO: 34).
[0263] (g-1) PCR was carried out in the same manner as in (e-1), except that oligonucleotides consisting of the sequences set forth in SEQ ID NO: 50 (5'-TTAACGAAGCCGTCGACCATCATCA-3') and SEQ ID NO: 51 (5'-ACGGCTTCGTTAACGGTCAAGTCTG-3') were used as PCR primers.
[0264] (g-2) From the PCR product obtained in (g-1), a plasmid (expression vector) pET-AVR29c containing a polynucleotide encoding AVR29c in which 29 amino acids were substituted relative to the native AAV binding protein was obtained in the same manner as in (a-2).
[0265] (g-3) The nucleotide sequence of pET-AVR29c was analyzed and confirmed in the same manner as in Example 2(8).
[0266] The amino acid sequence of AVR29c with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 37. In SEQ ID NO: 37, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR29c (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 37, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the phenylalanine of I366F is at position 79, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, the arginine of K380R is at position 93, and the alanine of V381A is at position 94. In the nucleotide sequence, the valine of I382V is at position 95, the serine of G390S is at position 103, the alanine of V394A is at position 107, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the arginine of K455R is at position 168, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, the aspartic acid of N492D is at position 205, and the glutamic acid of K497E is at position 210.
[0267] (h) AVR29d This protein was prepared by selecting V499I from the amino acid substitutions involved in alkaline stability identified in Example 8 and introducing this amino acid substitution into AVR28 (SEQ ID NO: 34).
[0268] (h-1) PCR was carried out in the same manner as in (e-1), except that oligonucleotides consisting of the sequences set forth in SEQ ID NO: 52 (5'-AAGCCATTGACCATCATCATCATCA-3') and SEQ ID NO: 53 (5'-TGGTCAATGGCTTTGTTAACGGTCA-3') were used as PCR primers.
[0269] (h-2) From the PCR product obtained in (h-1), a plasmid (expression vector) pET-AVR29d containing a polynucleotide encoding AVR29d, which had 29 amino acid substitutions relative to the native AAV binding protein, was obtained in the same manner as in (a-2).
[0270] (h-3) The nucleotide sequence of pET-AVR29d was analyzed and confirmed in the same manner as in Example 2(8).
[0271] The amino acid sequence of AVR29d with the signal sequence and polyhistidine tag added is shown in SEQ ID NO: 38. In SEQ ID NO: 38, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR29d (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 38, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the phenylalanine of I366F is at position 79, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, the arginine of K380R is at position 93, and the alanine of V381A is at position 94. In the nucleotide sequence, the valine of I382V is at position 95, the serine of G390S is at position 103, the alanine of V394A is at position 107, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the arginine of K455R is at position 168, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, the aspartic acid of N492D is at position 205, and the isoleucine of V499I is at position 212.
[0272] (i) AVR31 This protein was prepared by selecting K497E and V499I from the amino acid substitutions involved in alkaline stability identified in Example 8 and introducing these amino acid substitutions into AVR29b (SEQ ID NO: 36).
[0273] (i-1) PCR was performed in the same manner as in (a-1), except that the vector pET-AVR29b capable of expressing a polypeptide containing AVR29b (SEQ ID NO: 36) was used as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 54 (5'-AACGAAGCCATTGACCATCATCATCATCATCAT-3') and SEQ ID NO: 55 (5'-GTCAATGGCTTCGTTAACGGTCAAGTCTGC-3') were used as PCR primers.
[0274] (i-2) From the PCR product obtained in (i-1), a plasmid (expression vector) pET-AVR31 containing a polynucleotide encoding AVR31 in which 31 amino acid substitutions were made relative to the native AAV binding protein was obtained in the same manner as in (a-2).
[0275] (i-3) The nucleotide sequence of pET-AVR31 was analyzed and confirmed in the same manner as in Example 2(8).
[0276] The amino acid sequence of AVR31 with a signal sequence and a polyhistidine tag added is shown in SEQ ID NO: 39. In SEQ ID NO: 39, the portion from methionine (M) at position 1 to alanine (A) at position 22 represents the PelB signal peptide, the portion from serine (S) at position 25 to aspartic acid (D) at position 213 represents the AAV binding protein AVR31 (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the portion from histidine (H) at positions 214 to 219 represents the tag sequence. In SEQ ID NO: 39, the aspartic acid of G314D is at position 27, the aspartic acid of V317D is at position 30, the histidine of N324H is at position 37, the alanine of V326A is at position 39, the lysine of N329K is at position 42, the valine of A330V is at position 43, the leucine of Q334L is at position 47, the valine of E335V is at position 48, the alanine of T341A is at position 54, the serine of Y342S is at position 55, the glutamic acid of K362E is at position 75, the phenylalanine of I366F is at position 79, the asparagine of K371N is at position 84, the tyrosine of F379Y is at position 92, the arginine of K380R is at position 93, and the alanine of V381A is at position 94. In the nucleotide sequence, the valine of I382V is at position 95, the serine of G390S is at position 103, the alanine of V394A is at position 107, the glutamic acid of K399E is at position 112, the glycine of E401G is at position 114, the alanine of T426A is at position 139, the arginine of K455R is at position 168, the proline of A461P is at position 174, the asparagine of K467N is at position 180, the arginine of S476R is at position 189, the threonine of S482T is at position 195, the aspartic acid of N487D is at position 200, the aspartic acid of N492D is at position 205, the glutamic acid of K497E is at position 210, and the isoleucine of V499I is at position 212.
[0277] Example 10 Preparation of AVR25c Amino Acid Substitution Assembly (Part 2) (1) As transformants capable of expressing AAV-binding proteins, transformants obtained by transforming Escherichia coli strain BL21(DE3) with plasmids containing polynucleotides encoding any of the nine types of AAV-binding proteins obtained in Example 9 (AVR25c amino acid substitution assembly, specifically AVR27b (SEQ ID NO: 31), AVR27c (SEQ ID NO: 32), AVR27d (SEQ ID NO: 33), AVR28 (SEQ ID NO: 34), AVR29a (SEQ ID NO: 35), AVR29b (SEQ ID NO: 36), AVR29c (SEQ ID NO: 37), AVR29d (SEQ ID NO: 38), and AVR31 (SEQ ID NO: 39)), and AVR21 (SEQ ID NO: 2) and AVR25c (SEQ ID NO: 28) were used. The transformants were cultured and the bacterial cells were collected in the same manner as in Example 4(1) to (4), except that the following were used.
[0278] (2) Bugbuster 10x (Novagen) was mixed at 1 / 10 of the total volume with 20 mM Tris-HCl buffer (pH 7.4) containing 20 mM imidazole (hereinafter also referred to as "equilibration solution D") at 25 U / mL, and the resulting mixture was used to suspend the bacterial cells recovered in (1) at 5 mL / 1 g (bacterial cells), followed by shaking at 15 ° C for 20 minutes to disrupt the cells. The disrupted bacterial cell solution was centrifuged at 8000 rpm for 20 minutes at 4 ° C, and each supernatant was collected.
[0279] (3) The supernatant obtained in (2) was applied to an open column packed with 1.5 mL of Ni-NTAAgarose (Fujifilm Wako Pure Chemical Industries, Ltd.) that had been previously equilibrated with equilibration solution D. After washing with equilibration solution A, elution was performed with 20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M imidazole.
[0280] (4) Each eluate obtained in (3) was desalted using a PD MiniTrap G-25 (manufactured by Cytiva) to prepare an AAV-binding protein solution.
[0281] Example 11 Evaluation of alkaline stability of AVR25c amino acid substitution aggregates (part 1) Of the AAV-binding proteins prepared in Example 10, AVR25c (SEQ ID NO: 28), AVR28 (SEQ ID NO: 34), and AVR29a (SEQ ID NO: 35) were used to evaluate alkaline stability.
[0282] (1) The concentration of the AAV-binding protein solution prepared in Example 10 was measured using NanoDrop OneC (Thermo Fisher Scientific), and then the solution was diluted with 20 mM Tris-HCl buffer (pH 7.4) to a protein concentration of 5 μg / mL.
[0283] (2) Each AAV-binding protein solution diluted in (1) was mixed with an equal volume of 1 M aqueous sodium hydroxide solution containing 1 mM calcium chloride, and subjected to alkali treatment by leaving the mixture at a constant temperature for a certain period of time (treatment temperature: 30°C, treatment time: 0, 30, 60 minutes).
[0284] (3) The fraction after treatment in (2) was mixed with 0.5 M MES buffer (pH 6.0) in a ratio of 8:2 to adjust the pH to around 6, and then the binding activity to VLP2 was measured using the ELISA method described in Example 2(6).
[0285] (4) The residual activity was calculated by dividing the absorbance at 450 nm after the alkali treatment in (3) by the absorbance at 450 nm after the treatment time of 0 hours.
[0286] The results are shown in Table 10. It can be seen that both AVR28 (SEQ ID NO: 34) and AVR29a (SEQ ID NO: 35) have higher residual activity and improved alkali stability compared to AVR25c (SEQ ID NO: 28).
[0287]
[0288] Example 12 Evaluation of alkaline stability of AVR25c amino acid substitution aggregates (part 2) Evaluation of alkaline stability was carried out using AVR25c (SEQ ID NO: 28), AVR27b (SEQ ID NO: 31), AVR27c (SEQ ID NO: 32), and AVR27d (SEQ ID NO: 33) from the AAV-binding proteins prepared in Example 10. The evaluation was carried out in the same manner as in Example 11, except that the treatment time was 0, 30, or 45 minutes.
[0289] The results are shown in Table 11. It can be seen that AVR27b (SEQ ID NO: 31), AVR27c (SEQ ID NO: 32), and AVR27d (SEQ ID NO: 33) all have higher residual activity and improved alkali stability compared to AVR25c (SEQ ID NO: 28).
[0290]
[0291] Example 13 Evaluation of alkaline stability of AVR25c amino acid substitution aggregate (part 3) Of the AVR25c amino acid substitution aggregates prepared in Example 10, alkaline stability was evaluated using AVR25c (SEQ ID NO: 28), AVR29b (SEQ ID NO: 36), AVR29c (SEQ ID NO: 37), and AVR29d (SEQ ID NO: 38). The evaluation was performed in the same manner as in Example 11, except that the treatment time was 0, 20, or 45 minutes.
[0292] The results are shown in Table 12. It can be seen that AVR29b (SEQ ID NO: 36), AVR29c (SEQ ID NO: 37), and AVR29d (SEQ ID NO: 38) all have higher residual activity and improved alkali stability compared to AVR25c (SEQ ID NO: 28).
[0293]
[0294] Example 14 Evaluation of alkaline stability of AVR25c amino acid substitution aggregates (part 4) Evaluation of alkaline stability was carried out using AVR28 (SEQ ID NO: 34), AVR29b (SEQ ID NO: 36), AVR29c (SEQ ID NO: 37), and AVR29d (SEQ ID NO: 38) from the AAV-binding proteins prepared in Example 10. The evaluation was carried out in the same manner as in Example 11, except that the treatment time was 0, 20, or 60 minutes.
[0295] The results are shown in Table 13. AVR29b (SEQ ID NO: 36), AVR29c (SEQ ID NO: 37), and AVR29d (SEQ ID NO: 38) all had higher residual activity than AVR28 (SEQ ID NO: 34), indicating improved alkali stability.
[0296]
[0297] Example 15 Evaluation of alkaline stability of AVR25c amino acid substitution aggregates (part 5) Of the AAV-binding proteins prepared in Example 10, AVR25c (SEQ ID NO: 28), AVR28 (SEQ ID NO: 34), AVR29c (SEQ ID NO: 37), and AVR31 (SEQ ID NO: 39) were used to evaluate alkaline stability by the method described in Example 11.
[0298] The results are shown in Table 14. It can be seen that AVR28 (SEQ ID NO: 34), AVR29c (SEQ ID NO: 37), and AVR31 (SEQ ID NO: 39) all have higher residual activity and improved alkali stability compared to AVR25c (SEQ ID NO: 28).
[0299]
[0300] Example 16: Evaluation of alkaline stability of AVR25c amino acid substitution aggregates (part 6) Of the AAV-binding proteins prepared in Example 10, AVR21 (SEQ ID NO: 2), AVR25c (SEQ ID NO: 28), and AVR31 (SEQ ID NO: 39) were used to evaluate alkaline stability by the method described in Example 11.
[0301] The results are shown in Table 15. It can be seen that AVR31 (SEQ ID NO: 39) has higher residual activity and improved alkali stability compared to AVR21 (SEQ ID NO: 2) and AVR25c (SEQ ID NO: 28).
[0302]
[0303] Example 17 Preparation and Evaluation of AAV-Binding Protein-Immobilized Gel (1) A gel was prepared by chemically modifying the surface hydroxyl groups of a hydrophilic vinyl polymer for separation agents (Toyopearl, manufactured by Tosoh Corporation) to introduce iodoacetamide groups. To 1.0 g of the prepared gel, 6 mg of AVR29c (SEQ ID NO: 37) as the AAV-binding protein prepared in Example 10 and TCEP (Tris(2-CarboxyEthyl)Phosphine) at a final concentration of 0.3 mM as a reducing agent were added, and the mixture was allowed to react for 3 hours under conditions of pH 7.4 and 25°C with shaking. This resulted in the preparation of a gel in which AVR29c, an AAV adsorbent, was immobilized (designated AVR29c-immobilized gel).
[0304] (2) 2.0 mL of the AVR29c-immobilized gel prepared in (1) was packed into an empty column (φ10 mm × 50 mm, manufactured by Cytiva) to prepare an AAV adsorbent column (hereinafter also referred to as "AVR29c column").
[0305] (3) The AVR29c column prepared in (2) was equilibrated with 20 mM Tris-HCl buffer (pH 8.0) containing 0.15 mM sodium chloride (hereinafter also referred to as "equilibration solution E"). (4) The AAV8-EGFP solution obtained in Example 5 was applied to the column, washed with equilibration solution E, and then eluted with 0.1 M acetate buffer (pH 2.5) containing 0.15 M sodium chloride (hereinafter also referred to as "elution solution B") to obtain a solution of the AAV vector AAV8-EGFP.
[0306] The obtained chromatogram is shown in Figure 1. In Figure 1, the peak indicated by the black arrow corresponds to the peak of the fraction containing the AAV vector (AAV8-EGFP). Most of the impurities contained in the AAV8-EGFP solution passed through the AVR29c column, demonstrating that the AAV vector contained in the solution can be purified using the AVR29c column.
[0307] Example 18 Purification by Combination of Affinity Chromatography and Anion Exchange Chromatography (Part 1) The AAV vector solution after affinity chromatography purification was applied to an anion exchange column to attempt further purification of the AAV vector.
[0308] (1) The AAV vector solution obtained in Example 17(4) was diluted 5-fold with 20 mM Tris-HCl buffer (pH 9.0) (hereinafter also referred to as solution AEX-A) to prepare a sample to be applied to an anion exchange column.
[0309] (2) The sample prepared in (1) was applied at a rate of 0.1 mL / min to a column (hereinafter also referred to simply as "GigaCapQ column") prepared by packing 0.5 mL of TOYOPEARL GigaCapQ-650S (a high-adsorption anion exchange chromatography support for separation and purification, manufactured by Tosoh Corporation) in an empty column (φ5 mm × 50 mm, manufactured by Cytiva Co., Ltd.) that had been previously equilibrated with solution AEX-A.
[0310] (3) The GigaCapQ column was washed by flowing 10 CV (Column Volume) of solution AEX-A at 0.5 mL / min, and then a linear gradient was applied until the concentration of solution AEX-A containing 1 M choline chloride (hereinafter also referred to as solution AEX-B) reached 14.5%, and impurities were eluted by running the solution for 60 CV while maintaining this state (state in which AEX-B was 14.5%).
[0311] (4) A step gradient of 35% AEX-B solution was applied to elute the AAV vector (AAV8-EGFP).
[0312] The obtained chromatogram is shown in Figure 2. In Figure 2, the peak indicated by the black arrow corresponds to the peak of the fraction containing the AAV vector (AAV8-EGFP). The impurities remaining in the AAV vector solution obtained in Example 18(4) were removed using an anion exchange column (the peak indicated by the white arrow in Figure 2 corresponds to the impurities). These results demonstrate that the purity of the AAV vector can be further improved by purifying the solution containing the AAV vector using affinity chromatography using an AAV-binding protein-immobilized gel, followed by further purification using anion exchange chromatography.
[0313] Example 19 Measurement of the Proportion of AAV Vectors Containing Genes (Full Rate) The proportion of AAV vectors containing genes (full rate) among the AAV vectors contained in the fraction obtained in Example 17(4) (peak indicated by the black arrow in Figure 1 ) and in the fractions obtained in Example 18(3) (peak indicated by the white arrow in Figure 2 ) and Example 18(4) (peak indicated by the black arrow in Figure 2 ) was measured by the method described below.
[0314] (1) Each fraction was diluted 4-fold with solution AEX-A and applied to a column for anion exchange chromatography, TSKgel Q-STAT (manufactured by Tosoh Corporation).
[0315] (2) A gene-free (Empty) AAV vector was eluted by applying a linear gradient at a flow rate of 1 mL / min so that the solution AEX-B became 17.0% in 7 minutes.
[0316] (3) After maintaining the solution AEX-B at 17.0% for 3 minutes, a linear gradient was applied at a flow rate of 1 mL / min so that the solution AEX-B became 45.0% over 10 minutes, thereby eluting the gene-containing (full) AAV vector.
[0317] (4) The peak areas of the fraction obtained in (2) (containing empty AAV vectors) and the fraction obtained in (3) (containing full AAV vectors) were quantified based on the fluorescence intensity at 350 nm in response to 280 nm excitation light, and the proportion of full AAV vectors (full rate) was calculated by determining the ratio of the peak area of fraction (3) to the sum of the peak areas of fractions (2) and (3).
[0318] The fullness was calculated as follows: the fraction obtained in Example 17(4), i.e., the purified fraction on the AVR29c column, was 12.1%, the fraction obtained in Example 18(3), i.e., the wash fraction on the GigaCapQ column, was 8.5%, and the fraction obtained in Example 18(4), i.e., the purified fraction on the GigaCapQ column, was 82%. These results demonstrate that purifying a solution containing an AAV vector by affinity chromatography using an AAV adsorbent and then further purifying it by anion exchange chromatography not only improves the purity of the AAV vector, but also improves the fullness (i.e., the proportion of AAV vectors containing genes).
[0319] Reference Example 3 AAV Purification Using Anion Exchange Chromatography Only (1) The AAV8-EGFP solution obtained in Example 5 was adjusted to pH 9.0 using Tris buffer.
[0320] (2) The AAV8-EGFP solution whose pH had been adjusted in (1) was purified using a GigaCap Q column by the method described in Example 18 (2) to (4).
[0321] (3) Each of the obtained fractions (peaks) was purified using TSKgel G6000PW XL The analysis was carried out using a column packed with size exclusion chromatography gel (manufactured by Tosoh Corporation).
[0322] The results of purification using the GigaCap Q column (chromatogram) are shown in Figure 3. XL The analytical results for each of the above are shown in Figure 4. The black arrows in Figure 4 correspond to the peaks of fractions containing AAV vectors (AAV8-EGFP). Although peaks corresponding to AAV vectors were confirmed in Peaks 2 to 4 in Figure 3, it was also found that many impurities were also contained. These results demonstrate that it is difficult to obtain highly pure AAV by purifying a solution containing AAV vectors using only anion exchange chromatography.
[0323] Example 20 Preparation of AAV-binding protein from which signal peptide sequence has been removed (1) PCR was performed in the same manner as in Example 10(a-1), except that a vector capable of expressing AVR29c (SEQ ID NO: 37) was used as a template and oligonucleotides consisting of the sequences set forth in SEQ ID NO: 56 (5'-ACATATGTCTGCAGGCGAAAGCGAC-3') and SEQ ID NO: 57 (5'-CCTGCAGACATATGTATATCTCCTTC-3') were used as PCR primers.
[0324] (2) From the PCR product obtained in (1), a plasmid (expression vector) pET-AVR29c(-) was obtained in the same manner as in Example 9(a-2), which encodes AVR29c, which has 29 amino acid substitutions relative to the native AAV binding protein, and which contains a polynucleotide lacking a signal sequence on the N-terminal side.
[0325] (3) The nucleotide sequence of pET-AVR29c(-) was analyzed and confirmed in the same manner as in Example 2(8).
[0326] The amino acid sequence of AVR29c(-) tagged with a polyhistidine is shown in SEQ ID NO: 58. In SEQ ID NO: 58, the sequence from the serine (S) at position 2 to the aspartic acid (D) at position 190 represents the AAV binding protein AVR29c(-) (corresponding to the region from positions 25 to 213 in SEQ ID NO: 2), and the histidines (H) at positions 191 to 196 represent the tag sequence. In SEQ ID NO: 58, the aspartic acid of V317D is at the 7th position, the histidine of N324H is at the 14th position, the alanine of V326A is at the 16th position, the lysine of N329K is at the 19th position, the valine of A330V is at the 20th position, the leucine of Q334L is at the 24th position, the valine of E335V is at the 25th position, the alanine of T341A is at the 31st position, the serine of Y342S is at the 32nd position, the glutamic acid of K362E is at the 52nd position, the phenylalanine of I366F is at the 56th position, the asparagine of K371N is at the 61st position, the tyrosine of F379Y is at the 69th position, the arginine of K380R is at the 70th position, and the alanine of V381A is at the 71st position. th, valine of I382V is at position 72, serine of G390S is at position 80, alanine of V394A is at position 84, glutamic acid of K399E is at position 89, glycine of E401G is at position 91, alanine of T426A is at position 116, arginine of K455R is at position 145, proline of A461P is at position 151, asparagine of K467N is at position 157, arginine of S476R is at position 166, threonine of S482T is at position 172, aspartic acid of N487D is at position 177, aspartic acid of N492D is at position 182, and glutamic acid of K497E is at position 187.
[0327] (4) The transformant was cultured in the same manner as in Example 4(1) to (4), and the cells were collected, except that the Escherichia coli strain BL21(DE3) was transformed with the plasmid containing the polynucleotide encoding the AAV-binding protein AVR29c(-) (SEQ ID NO: 58) obtained in (3).
[0328] (5) An AVR29c(-) solution was prepared from the cells collected in the same manner as in (2) to (4) of Example 10.
[0329] (6) AVR29c prepared in Example 10 and AVR29c(-) prepared in (5) were subjected to SDS-PAGE and stained with CBB (Coomassie Brilliant Blue) staining solution (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.).
[0330] The results are shown in Figure 5. In AVR29c(-) (SEQ ID NO: 58, lane 2), AVR29c + His tag was observed as the main band, whereas in AVR29c (SEQ ID NO: 37, lane 3), AVR29c + His tag with the signal peptide PelB remaining and AVR29c + His tag with PelB cleaved were mixed, indicating low homogeneity.
[0331] Example 21 Performance Evaluation of AAV-Binding Proteins AVR29c (SEQ ID NO: 37) prepared in Example 10 and AVR29c(-) prepared in Example 20 (SEQ ID NO: 58) were used to evaluate their binding to AAV.
[0332] (1) VLP2 prepared in Example 1 was immobilized on the wells of a 96-well microplate (manufactured by Thermo Fisher Scientific) and blocked by the method described in Example 2 (6-1).
[0333] (2) After washing the wells with the washing buffer described in Example 2(6-2), a solution containing AVR29c or AVR29c(-) was added to the wells and reacted with VLP2 (1 hour at 30°C). (3) After the reaction was completed, an elution buffer (200 mM acetate buffer (pH 3.0 or pH 2.0) containing 0.5 M sodium chloride) or 20 mM Tris-HCl buffer (pH 7.4) in the same volume as the solution added in (2) was added, and the reaction was allowed to proceed at 25°C for 10 minutes.
[0334] (4) After the reaction was completed, the solution in the wells was removed, and the wells were washed with the washing buffer described in Example 2 (6-2). Then, 100 μL / well of anti-6His antibody (manufactured by Bethyl Laboratories) diluted to 100 ng / mL was added.
[0335] (5) Reaction and absorbance measurement were performed in the same manner as in (6-4) of Example 2. The remaining rate of AAV-binding protein in the well was calculated by dividing the absorbance of the well after the reaction with the elution buffer in (3) by the absorbance of the well after the reaction with the Tris-HCl buffer.
[0336] The measurement results are shown in Figure 6. The residual rate of the AAV-binding protein in the well after addition of the elution buffer (acetate buffer) was lower for AVR29c(-) (SEQ ID NO: 58) than for AVR29c (SEQ ID NO: 37), and AVR29c(-) was more efficiently dissociated from VLP2 immobilized in the well. As shown in Figure 5 (Example 20), AVR29c(-) (SEQ ID NO: 58) has higher homogeneity as an AAV-binding protein than AVR29c (SEQ ID NO: 37). Therefore, it is presumed that this high homogeneity enables efficient dissociation of AAV by addition of the elution buffer.
[0337] Example 22 Preparation of AAV-binding protein-immobilized gel and performance evaluation (1) A gel (designated AVR29c(-)-immobilized gel) was prepared by immobilizing AVR29c(-) prepared in Example 22 on a hydrophilic vinyl polymer for a separating agent in the same manner as in Example 13(1).
[0338] (2) Approximately 10 mg of the AVR29c-immobilized gel prepared in Example 13(1) and the AVR29c(-)-immobilized gel prepared in Example 13(1) were added to a 0.2 μm Cosmos spin filter (manufactured by Nacalai Tesque), and 9.7 × 10 12 After adding the AAV8-EGFP to the immobilized gel, the mixture was stirred at 25°C for 1 hour to allow the AAV8-EGFP to be adsorbed onto the immobilized gel.
[0339] (3) After removing the AAV8-EGFP solution from the immobilized gel by centrifugation, 100 μL of a washing solution (20 mM Tris-HCl buffer (pH 7.4) containing 0.5 M sodium chloride and 0.5 mM calcium chloride) was added, and the gel was washed by stirring at 25°C for 3 minutes.
[0340] (4) After separating and removing the washing solution from (3) from the immobilization gel by centrifugation, 100 μL of eluent A (0.1 M acetate buffer (pH 3.0) containing 0.5 M sodium chloride) was added and stirred at 25° C. for 3 minutes. After stirring, eluent A was separated from the immobilization gel by centrifugation, thereby eluting AAV8 adsorbed to the immobilization gel. This procedure was repeated once more, and the two eluted fractions were combined and designated "fraction A."
[0341] (5) 100 μL of eluent B (0.1 M acetic acid (pH 2.5) containing 0.5 M sodium chloride) was added, and the mixture was stirred at 25° C. for 3 minutes. After stirring, the eluent B was separated from the immobilization gel by centrifugation, thereby eluting the AAV8 remaining in the immobilization gel. This procedure was repeated once more, and the two eluted fractions were combined and designated "fraction B."
[0342] (6) 100 μL of eluent C (0.1 M acetic acid (pH 2.0) containing 0.5 M sodium chloride) was added and stirred at 25° C. for 3 minutes. After stirring, eluent C was separated from the immobilization gel by centrifugation, thereby eluting AAV8 remaining in the immobilization gel. This procedure was repeated once more, and the two eluted fractions were combined and designated "fraction C."
[0343] (7) A size exclusion chromatography column, TSKgel G6000PW (manufactured by Tosoh Corporation), was connected to an ultra-high performance liquid chromatograph, Nexera (manufactured by Shimadzu Corporation), and equilibrated with eluent A (50 mM sodium acetate buffer (pH 6.0) containing 0.5 M sodium chloride, 0.01% (w / v) Tween 20 (manufactured by Sigma-Aldrich), and 0.01% (w / v) Pluronic F-68 (manufactured by Sigma-Aldrich)).
[0344] (8) AAV8-EGFP of known concentration, as well as fraction A obtained in (4), fraction B obtained in (5), and fraction C obtained in (6) were each applied to the column equilibrated in (7) and pumped at a flow rate of 1 mL / min to obtain a separated peak derived from AAV8-EGFP for each sample. The separated peak was detected by fluorescence intensity (excitation at 280 nm / emission at 350 nm).
[0345] (9) Based on the areas of the separated peaks obtained with AAV8-EGFP of known concentrations, the concentrations of AAV8 contained in fractions A, B, and C were quantified.
[0346] The results are shown in Figure 7. In the AVR29c-immobilized gel, the AAV8 concentration was highest in fraction C (pH 2.0), whereas in the AVR29c(-)-immobilized gel, the AAV8 concentration was highest in fraction B (pH 2.5). As shown in Figure 5 (Example 20), AVR29c(-) (SEQ ID NO: 58), which is used as the ligand for the immobilized gel, has higher homogeneity as an AAV-binding protein than AVR29c (SEQ ID NO: 37). Therefore, it is presumed that this high homogeneity enables AAV elution under milder conditions.
[0347] Example 23 Purification by Combination of Affinity Chromatography and Anion Exchange Chromatography (Part 2) (1) The AVR29c column prepared in Example 17 was equilibrated with 20 mmol / L Tris-HCl buffer (pH 7.4) containing 500 mmol / L sodium chloride (hereinafter also referred to as "equilibration solution D").
[0348] (2) The AAV8-EGFP solution obtained in Example 5 was applied to an AVR29c column, washed with equilibration solution D, and then eluted with 20 mmol / L Tris-HCl buffer (pH 7.4) containing 2.0 mol / L magnesium chloride to obtain an AAV8-EGFP solution, which is an AAV vector.
[0349] (3) The AAV vector (AAV8-EGFP) solution obtained in (2) was dialyzed against 100 times the volume of solution AEX-A to prepare a sample to be applied to an anion exchange column.
[0350] (4) The AAV8-EGFP solution prepared in (3) was applied at a rate of 0.1 mL / min to 1.0 mL of SkillPak TOYOPEARL GigaCapQ-650S (a prepacked column of support for high-adsorption anion exchange chromatography for separation and purification, manufactured by Tosoh Corporation; hereinafter, also simply referred to as "SkillPak GigaCapQ column"), which had been equilibrated in advance with solution AEX-A.
[0351] (5) The SkillPak GigaCapQ column was washed by flowing 2 CV of solution AEX-A at 0.5 mL / min, and then the conductivity of the solution was changed by adjusting the mixing ratio of solution AEX-A and 20 mmol / L Tris-HCl buffer (pH 9.0) containing 300 mmol / L choline chloride (hereinafter also referred to as “solution AEX-C”), thereby eluting the impurities adsorbed to the column. Specifically, the mixing ratio of solution AEX-C was adjusted to any one of the following: (a) 49.0% (electrical conductivity: 13.3 mS / cm (millisiemens per centimeter)), (b) 48.0% (electrical conductivity: 13.0 mS / cm), (c) 47.0% (electrical conductivity: 12.8 mS / cm), and (d) 46.5% (electrical conductivity: 12.7 mS / cm). Impurities were eluted by flowing the solution for 30 to 60 CV while maintaining this condition.
[0352] (6) A step gradient was applied to the column, with the AEX-C solution being 100% (conductivity: 24.5 mS / cm), to elute the AAV vector (AAV8-EGFP).
[0353] (7) The proportion of full AAV contained in the eluted fractions obtained in (5) and (6) was measured by mass photometry using Refeyn Two (Refeyn).
[0354] The resulting chromatograms are shown in Figure 8. The fullness of the AAV vector contained in the elution fractions obtained in (5) (the peak indicated by the white arrow in Figure 8) and (6) (the peak indicated by the black arrow in Figure 8) was measured, and the results are shown in Table 16. It can be seen that a solution containing an AAV vector with a higher fullness can be obtained by setting the conductivity of the eluate used to elute impurities to 13.5 mS / cm or less and the conductivity of the eluate used to elute the AAV vector to 15.0 mS / cm or more.
[0355]
[0356] Example 24 Purification by Combining Affinity Chromatography and Anion Exchange Chromatography (Part 3) (1) The AAV8-EGFP solution obtained in Example 5 was purified on an AVR29c column by the method described in Example 23 (1) to (3) to prepare a sample (AAV8-EGFP solution) to be applied to an anion exchange column.
[0357] (2) The AAV8-EGFP solution prepared in (1) was applied at a rate of 0.1 mL / min to a 5.0 mL SkillPak GigaCapQ column that had been previously equilibrated with solution AEX-A.
[0358] (3) The SkillPak GigaCapQ column was washed by flowing 2 CV of solution AEX-A at 0.5 mL / min, and then the mixing ratio was adjusted so that the ratio of solution AEX-C was 46.0% (electrical conductivity: 12.5 mS / cm). Impurities were eluted by flowing 20 CV while maintaining this condition.
[0359] (4) A step gradient was applied to the column, with the AEX-C solution being 100% (conductivity: 24.5 mS / cm), to elute the AAV vector (AAV8-EGFP).
[0360] (5) The full fractions contained in the AAV8-EGFP solution obtained in (1) and the eluted fractions obtained in (3) and (4) were measured by mass photometry using Refeyn Two (Refeyn).
[0361] The chromatogram obtained by affinity chromatography (AF) purification (purification using an AVR29c column) is shown in Figure 9(a), and the chromatogram obtained by anion exchange chromatography (AEX) purification (purification using a SkillPak GigaCapQ column) is shown in Figure 9(b). Table 17 shows the results of measuring the full percentage of AAV vector contained in the AAV8-EGFP solution obtained in (1) (the peak indicated by the black arrow in Figure 9(a) , the AF-purified fraction), (3) (the peak indicated by the white arrow in Figure 9(b) , Fr18), and (4) (the peak indicated by the black arrow in Figure 9(b) , Fr38) elution fractions. It can be seen that even when the capacity of the SkillPak GigaCapQ column is increased from 1.0 mL (Example 23) to 5.0 mL, a solution containing an AAV vector with a high fullness rate can be obtained by the purification method of the present disclosure.
[0362]
[0363] Example 25 Evaluation of infectivity after anion exchange chromatography purification The AF purified fraction obtained in Example 24(1), Fr18 obtained in Example 24(3), and Fr38 obtained in Example 24(4) were each dialyzed against PBS (Phosphate Buffered Saline) containing 1 mmol / L magnesium chloride, and then infected with AAV-HT1080 cells (Agilent Technologies) at 62,500 to 10 particles per cell. 6 particles were infected.
[0364] The number of particles per cell was determined using a size exclusion chromatography column (G6000PW XL A calibration curve was prepared using a column.
[0365] 3 days, 5% CO 2 The cells were cultured in PBS at 37°C and then harvested. The solution was suspended several times with a pipette, and the fluorescence intensity derived from EGFP expressed in each cell was measured using Guava easyCyte (Luminex). The percentage of cells showing increased fluorescence intensity compared to cells not receiving the AAV infection solution was measured, thereby calculating the percentage of cells infected with the AAV8 mutant vector (infection rate).
[0366] The results of comparing the positive rates 3 days after infection are shown in FIG.
[0367] The infection dose shown on the X axis is expressed as the number of particles per cell in Fig. 10(a) and as the number of vector genomes (VG) per cell calculated based on the full rate measured in Example 10(5) in Fig. 10(b). Fig. 10(b) does not include the results of infecting cells with particles in Fr18 obtained in Example 24(3) because it is outside the scope of the figure.
[0368] The number of vector genomes per cell was measured by qPCR. The PCR device was a QuantStudio3 Real-Time PCR System (Thermo Fisher Scientific). Pretreatment was performed using the reagents included with the AAVpro Titration Kit (Takara Bio Inc.). DNase I treatment was performed according to the protocol, and a portion was detected by PCR. The PCR reagent was TaqPath qPCR Master Mix (Thermo Fisher Scientific). The primers used were SEQ ID NO: 59 (CTCCATCACTAGGGGTTC) and 60 (TTGGGATTCCAGGCATGC). The probe used was a TaqMan probe with FAM attached to SEQ ID NO: 61 (TCCCTTCCCTGTCCTT). A calibration curve of the vector concentration in the obtained solution was prepared using the positive standard attached to the AAVpro Titration Kit (manufactured by Takara Bio Inc.).
[0369] The positive rates corresponded in order to Fr38 (black circles), the AF-purified fraction (black triangles), and Fr18 (white circles, not shown in Figure 7(b) because they are outside the range), and also to the full rates measured in Example 24(5). These results demonstrate that, in the purification method of the present disclosure, adding choline chloride to the eluate of AAV adsorbed to an anion exchange chromatography carrier enables the purification of full AAV in a highly pure and infective state.
[0370] In one aspect, the adeno-associated virus (AAV) binding protein of the present disclosure is a protein in which amino acid residues at specific positions in the region corresponding to extracellular domain 1 (PKD1) and domain 2 (PKD2) of KIAA0319L (UniProt No. Q8IZA0) are substituted with other amino acid residues. The AAV binding protein of the present disclosure can have significantly improved alkaline resistance compared to conventional AAV binding proteins. Therefore, an AAV adsorbent that uses the AAV binding protein as a ligand can be washed with alkali and can be repeatedly used for AAV purification, and is therefore thought to be useful for industrial AAV production.
[0371] In one aspect, the present disclosure provides a method for purifying AAV contained in a sample, the method comprising the steps of: adding a sample containing AAV to an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the carrier, thereby adsorbing the AAV to the adsorbent; eluting the AAV adsorbed to the adsorbent with an elution solution; adding a fraction containing AAV eluted in the elution step to an anion exchange chromatography carrier, thereby adsorbing the AAV to the carrier; and eluting the AAV adsorbed to the carrier with an elution solution. Among AAV vectors contained in the sample, an AAV vector containing a gene with a therapeutic effect (full AAV vector) can be purified with high purity and in a simple manner.
Claims
1. An AAV-binding protein selected from any of the following (i) to (iii): (i) an AAV-binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO: 2, with the proviso that at least one of the following amino acid substitutions (1) to (74) has occurred in the amino acid residues at positions 25 to 213, and having AAV-binding activity; (1) Threonine at position 139 in SEQ ID NO: 2 is replaced with Alanine; (2) Isoleucine at position 32 in SEQ ID NO: 2 is replaced with Asparagine; (3) Leucine at position 34 in SEQ ID NO: 2 is replaced with Glutamine; (4) Leucine at position 41 in SEQ ID NO: 2 is replaced with Proline; (5) Asparagine at position 42 in SEQ ID NO: 2 is replaced with Lysine or Serine; (6) Valine at position 45 in SEQ ID NO: 2 is replaced with Alanine; (7) Valine at position 48 in SEQ ID NO: 2 is replaced with Alanine; (8) Lysine at position 51 in SEQ ID NO: 2 is replaced with Arginine; (9) Glutamic acid at position 53 of SEQ ID NO:2 is replaced with glycine (10) Threonine at position 56 of SEQ ID NO:2 is replaced with alanine or serine (11) Tyrosine at position 57 of SEQ ID NO:2 is replaced with phenylalanine (12) Aspartic acid at position 58 of SEQ ID NO:2 is replaced with glycine (13) Glutamine at position 60 of SEQ ID NO:2 is replaced with lysine (14) Threonine at position 63 of SEQ ID NO:2 is replaced with alanine (15) Glutamic acid at position 73 of SEQ ID NO:2 is replaced with aspartic acid (16) Glutamine at position 78 of SEQ ID NO:2 is replaced with arginine (17) Isoleucine at position 79 of SEQ ID NO:2 is replaced with phenylalanine (18) Leucine at position 80 of SEQ ID NO:2 is replaced with proline (19) Lysine at position 81 of SEQ ID NO:2 is replaced with arginine (20) Leucine at position 82 of SEQ ID NO:2 is replaced with serine (21) Asparagine at position 84 of SEQ ID NO:2 is replaced with aspartic acid or serine. (22) Leucine at position 89 of SEQ ID NO:2 is replaced with proline. (23) Tyrosine at position 90 of SEQ ID NO:2 is replaced with phenylalanine or asparagine. (24) Glutamic acid at position 91 of SEQ ID NO:2 is replaced with glycine. (25) Tyrosine at position 92 of SEQ ID NO:2 is replaced with serine. (26) Alanine at position 94 of SEQ ID NO:2 is replaced with threonine.(27) Valine at position 95 of SEQ ID NO:2 is replaced with isoleucine (28) Glutamic acid at position 97 of SEQ ID NO:2 is replaced with aspartic acid (29) Histidine at position 102 of SEQ ID NO:2 is replaced with arginine (30) Valine at position 107 of SEQ ID NO:2 is replaced with alanine or isoleucine (31) Valine at position 109 of SEQ ID NO:2 is replaced with glutamic acid (32) Threonine at position 110 of SEQ ID NO:2 is replaced with alanine or serine (33) Glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine (34) Proline at position 115 of SEQ ID NO:2 is replaced with serine (35) Valine at position 125 of SEQ ID NO:2 is replaced with alanine (36) Aspartic acid at position 148 of SEQ ID NO:2 is replaced with alanine (37) Glutamic acid at position 166 of SEQ ID NO:2 is replaced with aspartic acid (38) Glutamic acid at position 167 of SEQ ID NO:2 is replaced with aspartic acid (39) Alanine at position 174 of SEQ ID NO:2 is replaced with proline (40) Serine at position 179 of SEQ ID NO:2 is replaced with threonine (41) Glutamine at position 180 of SEQ ID NO:2 is replaced with asparagine (42) Asparagine at position 185 of SEQ ID NO:2 is replaced with lysine (43) Lysine at position 210 of SEQ ID NO:2 is replaced with glutamic acid (44) Aspartic acid at position 213 of SEQ ID NO:2 is replaced with asparagine (45) Glycine at position 27 of SEQ ID NO:2 is replaced with aspartic acid (46) Aspartic acid at position 30 of SEQ ID NO:2 is replaced with glycine (47) Glutamine at position 31 of SEQ ID NO:2 is replaced with arginine (48) Proline at position 35 of SEQ ID NO:2 is replaced with alanine (49) Glutamic acid at position 38 of SEQ ID NO:2 is replaced with valine (50) Glutamine at position 60 of SEQ ID NO:2 is replaced with arginine. (51) Glutamic acid at position 75 of SEQ ID NO:2 is replaced with aspartic acid. (52) Histidine at position 76 of SEQ ID NO:2 is replaced with proline. (53) Tyrosine at position 92 of SEQ ID NO:2 is replaced with asparagine. (54) Glycine at position 105 of SEQ ID NO:2 is replaced with glutamic acid. (55) Valine at position 111 of SEQ ID NO:2 is replaced with alanine. (56) Glutamic acid at position 112 of SEQ ID NO:2 is replaced with lysine. (57) Arginine at position 119 of SEQ ID NO:2 is replaced with histidine. (58) Glutamine at position 128 of SEQ ID NO:2 is replaced with arginine.(59) Phenylalanine at position 129 of SEQ ID NO:2 is replaced with leucine (60) Leucine at position 134 of SEQ ID NO:2 is replaced with proline (61) Serine at position 146 of SEQ ID NO:2 is replaced with glycine (62) Threonine at position 147 of SEQ ID NO:2 is replaced with serine (63) Aspartic acid at position 150 of SEQ ID NO:2 is replaced with valine (64) Glutamic acid at position 158 of SEQ ID NO:2 is replaced with lysine (65) Lysine at position 168 of SEQ ID NO:2 is replaced with arginine (66) Serine at position 170 of SEQ ID NO:2 is replaced with arginine (67) Threonine at position 187 of SEQ ID NO:2 is replaced with arginine (68) Threonine at position 191 of SEQ ID NO:2 is replaced with isoleucine (69) Alanine at position 198 of SEQ ID NO:2 is replaced with valine (70) Threonine at position 199 of SEQ ID NO:2 is replaced with alanine (71) A substitution of leucine at position 206 in SEQ ID NO:2 with methionine; (72) A substitution of asparagine at position 209 in SEQ ID NO:2 with glutamic acid; (73) A substitution of valine at position 212 in SEQ ID NO:2 with isoleucine; (74) A substitution of aspartic acid at position 213 in SEQ ID NO:2 with glycine; (ii) An AAV binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, provided that at least one of the amino acid substitutions in (1) to (74) has occurred in the amino acid residues at positions 25 to 213, and further comprising any one or more of substitutions, deletions, insertions, and additions of one or several amino acid residues at one or several positions other than the amino acid substitutions in (1) to (74), and having AAV binding activity; (iii) An AAV binding protein comprising an amino acid sequence from the 25th serine to the 213th aspartic acid of the amino acid sequence set forth in SEQ ID NO: 2, which has an identity of 70% or more to the entire amino acid sequence in which at least one of the amino acid substitutions (1) to (74) has occurred, and in which the at least one amino acid substitution remains, and which has AAV binding activity.
2. The AAV binding protein according to claim 1, selected from any of the following (iv) to (vi): (iv) an AAV binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, with the proviso that at least the amino acid substitution set forth in (1) below has occurred in the amino acid residues at positions 25 to 213, and having AAV binding activity; (1) replacement of threonine at position 139 in SEQ ID NO:2 with alanine; (v) an AAV binding protein comprising at least the amino acid residues from serine at position 25 to aspartic acid at position 213 in the amino acid sequence set forth in SEQ ID NO:2, with the proviso that at least the amino acid substitution set forth in (1) has occurred in the amino acid residues at positions 25 to 213, and further comprising any one or more of substitutions, deletions, insertions and additions of one or several amino acid residues at one or several positions other than the amino acid substitutions set forth in (1), and having AAV binding activity; (vi) An AAV binding protein comprising an amino acid sequence from the serine at position 25 to the aspartic acid at position 213 of the amino acid sequence set forth in SEQ ID NO: 2, which has an identity of 70% or more to the entire amino acid sequence in which at least one of the amino acid substitutions of (1) has occurred, and in which at least one of the amino acid substitutions remains, and which has AAV binding activity.
3. The AAV binding protein according to claim 1, which contains at least the amino acid residues from the 25th serine to the 213th aspartic acid in the amino acid sequence set forth in SEQ ID NO:2, with the proviso that at least one of the following amino acid substitutions (A) to (P) has occurred in the amino acid residues from the 25th to the 213th, and has AAV binding activity; (A) the asparagine at the 42nd position of SEQ ID NO:2 is substituted with lysine, the glutamic acid at the 114th position of SEQ ID NO:2 is substituted with glycine, and the 139th threonine at the 139th position of SEQ ID NO:2 is substituted with alanine; (B) the 51st lysine at the 51st position of SEQ ID NO:2 is substituted with arginine, the 139th threonine at the 139th position of SEQ ID NO:2 is substituted with alanine, and the 174th alanine at the 174th position of SEQ ID NO:2 is substituted with proline. (C) Asparagine at position 42 of SEQ ID NO:2 is replaced with lysine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, and alanine at position 174 of SEQ ID NO:2 is replaced with proline. (D) Lysine at position 51 of SEQ ID NO:2 is replaced with arginine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, and alanine at position 174 of SEQ ID NO:2 is replaced with proline. (E) Asparagine at position 42 of SEQ ID NO:2 is replaced with lysine, lysine at position 51 of SEQ ID NO:2 is replaced with arginine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, and alanine at position 174 of SEQ ID NO:2 is replaced with proline. (F) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, and glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine.(G) Asparagine at position 42 of SEQ ID NO:2 is replaced with lysine, isoleucine at position 79 of SEQ ID NO:2 is replaced with phenylalanine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, alanine at position 174 of SEQ ID NO:2 is replaced with proline, glutamine at position 180 of SEQ ID NO:2 is replaced with asparagine, and threonine at position 187 of SEQ ID NO:2 is replaced with arginine. (H) Asparagine at position 42 of SEQ ID NO:2 is replaced with lysine, valine at position 107 of SEQ ID NO:2 is replaced with alanine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, alanine at position 174 of SEQ ID NO:2 is replaced with proline, glutamine at position 180 of SEQ ID NO:2 is replaced with asparagine, and threonine at position 187 of SEQ ID NO:2 is replaced with arginine. (I) Asparagine at position 42 of SEQ ID NO:2 is replaced with lysine, glutamic acid at position 114 of SEQ ID NO:2 is replaced with glycine, threonine at position 139 of SEQ ID NO:2 is replaced with alanine, lysine at position 168 of SEQ ID NO:2 is replaced with arginine, alanine at position 174 of SEQ ID NO:2 is replaced with proline, glutamine at position 180 of SEQ ID NO:2 is replaced with asparagine, and threonine at position 187 of SEQ ID NO:2 is replaced with arginine. (J) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, and glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine.(K) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and threonine at position 187 of SEQ ID NO:2 is substituted with arginine. (L) Glycine at position 27 of SEQ ID NO:2 is substituted with aspartic acid, asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, and glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine. (M) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid. (N) Asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, and valine at position 212 of SEQ ID NO:2 is substituted with isoleucine.(O) Glycine at position 27 of SEQ ID NO:2 is substituted with aspartic acid, asparagine at position 42 of SEQ ID NO:2 is substituted with lysine, isoleucine at position 79 of SEQ ID NO:2 is substituted with phenylalanine, valine at position 107 of SEQ ID NO:2 is substituted with alanine, glutamic acid at position 114 of SEQ ID NO:2 is substituted with glycine, threonine at position 139 of SEQ ID NO:2 is substituted with alanine, lysine at position 168 of SEQ ID NO:2 is substituted with arginine, alanine at position 174 of SEQ ID NO:2 is substituted with proline, glutamine at position 180 of SEQ ID NO:2 is substituted with asparagine, lysine at position 210 of SEQ ID NO:2 is substituted with glutamic acid, and valine at position 212 of SEQ ID NO:2 is substituted with isoleucine.
4. A polynucleotide encoding an AAV binding protein according to any one of claims 1 to 3.
5. An expression vector comprising the polynucleotide of claim 4.
6. A transformant obtained by transforming Escherichia coli with the expression vector according to claim 5.
7. A method for producing an AAV binding protein, comprising the steps of expressing the AAV binding protein by culturing the transformant described in claim 6, and recovering the expressed AAV binding protein from the resulting culture.
8. An AAV adsorbent comprising an insoluble carrier and an AAV binding protein according to any one of claims 1 to 3 immobilized on the carrier.
9. A column comprising the AAV adsorbent of claim 8.
10. A method for purifying or analyzing AAV, comprising the steps of adding a solution containing AAV to the column described in claim 9 to adsorb the AAV to the adsorbent, and eluting the AAV adsorbed to the adsorbent using an elution solution.
11. The method for purifying or analyzing AAV described in claim 10, further comprising a step of washing the AAV adsorbent with an alkaline solution after the step of eluting AAV.
12. A method for purifying AAV contained in a sample, comprising the steps of: adding a sample containing AAV to an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the insoluble carrier, thereby adsorbing the AAV to the adsorbent; eluting the AAV adsorbed to the adsorbent; adding a fraction containing AAV eluted in the elution step to an anion exchange chromatography carrier, thereby adsorbing the AAV to the anion exchange chromatography carrier; and eluting the AAV adsorbed to the anion exchange chromatography carrier.
13. A method for purifying AAV contained in a sample, comprising the steps of: adding a sample containing AAV to an adsorbent comprising an insoluble carrier and an AAV-binding protein immobilized on the insoluble carrier, thereby adsorbing the AAV to the adsorbent; eluting the AAV adsorbed to the adsorbent; adding a fraction containing AAV eluted in the elution step to an anion exchange chromatography carrier, thereby adsorbing the AAV to the anion exchange chromatography carrier; and eluting the AAV adsorbed to the anion exchange chromatography carrier, wherein the AAV-binding protein is an AAV-binding protein described in any one of claims 1 to 3.
14. A purification method according to claim 12 or 13, wherein the step of eluting the AAV adsorbed onto an anion exchange chromatography carrier comprises eluting the AAV adsorbed onto the carrier with an elution solution having a conductivity of 13.5 mS / cm or less, and then eluting the AAV remaining on the carrier with an elution solution having a conductivity of 15.0 mS / cm or more.
15. The purification method of claim 14, wherein the eluent comprises choline chloride.
Citation Information
Patent Citations
RECOMBINANT Fc RECEPTOR AND METHOD FOR PRODUCING THE SAME
JP2011097898A
Purification of Recombinant Adeno-Associated Virus Particles Including an Affinity Purification Step
JP2018507707A
Anion exchange chromatography for recombinant AAV production
JP2021526829A
Methods for producing recombinant AAV9 virion
JP2022138144A
Improved adeno-associated virus-binding protein, method for producing same, and adeno-associated virus adsorbent using same
WO2021106882A1
Cited By
Method for producing adeno-associated virus-binding protein
JP2026151214A
